

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

Date of mailing (day/month/year)
09 April 2001 (09.04.01)

To:	
ANNE RYAN & CO. 60 Northumberland Road Ballsbridge Dublin 4 IRLANDE	

Applicant's or agent's file reference
POO-18-PCT

IMPORTANT NOTIFICATION

International application No.
PCT/IE00/00026

International filing date (day/month/year)
28 February 2000 (28.02.00)

1. The following indications appeared on record concerning:

the applicant the inventor the agent the common representative

Name and Address	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

the person the name the address the nationality the residence

Name and Address McMAHON, Ruth, Anne 16 St. Patrick's Cottages Rathfarnham Dublin 14 Ireland	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

Additional applicant/inventor for the US only.

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Maria Victoria CORTIELLO
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

Date of mailing (day/month/year) 09 April 2001 (09.04.01)	
Applicant's or agent's file reference POO-18-PCT	IMPORTANT NOTIFICATION
International application No. PCT/IE00/00026	International filing date (day/month/year) 28 February 2000 (28.02.00)

1. The following indications appeared on record concerning:
- the applicant the inventor the agent the common representative

Name and Address	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:
- the person the name the address the nationality the residence

Name and Address MURPHY, Madeline, Anne 53 Meadow Grove Churchtown Dublin 16 Ireland	State of Nationality IE	State of Residence IE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:
Additional applicant/inventor for the US only.

4. A copy of this notification has been sent to:

- the receiving Office the designated Offices concerned
 the International Searching Authority the elected Offices concerned
 the International Preliminary Examining Authority other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Maria Victoria CORTIELLO Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 October 2000 (16.10.00)	
International application No. PCT/IE00/00026	Applicant's or agent's file reference POO-18-PCT
International filing date (day/month/year) 28 February 2000 (28.02.00)	Priority date (day/month/year) 26 February 1999 (26.02.99)

Applicant

BRADY, Hugh, Redmond et al

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

08 September 2000 (08.09.00)

in a notice effecting later election filed with the International Bureau on:

2. The election was

 was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Zakaria EL KHODARY Telephone No.: (41-22) 338.83.38
---	--

REC'D 12 JUN 2001

WIPO

PCT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference POO-18-PCT	FOR FURTHER ACTION		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/IE00/00026	International filing date (day/month/year) 28/02/2000	Priority date (day/month/year) 26/02/1999	
International Patent Classification (IPC) or national classification and IPC C12Q1/68			
Applicant HIBERGEN LIMITED et al			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 10 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application 			

Date of submission of the demand 08/09/2000	Date of completion of this report 07.06.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Luzzatto, E Telephone No. +49 89 2399 8169



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/IE00/00026

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):
Description, pages:

1,2,4-8,11-15,17-39, as originally filed
43,44

3,9,10,16,40-42 with telefax of 14/02/2001

Claims, No.:

1-11 with telefax of 14/02/2001

Sequence listing part of the description, pages:

1-11, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/IE00/00026

the claims, Nos.:
 the drawings, sheets:

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:
see separate sheet

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-11
No: Claims none

Inventive step (IS) Yes: Claims 1-11
No: Claims none

Industrial applicability (IA) Yes: Claims 1-11
No: Claims none

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

PART V

1) Novelty (Art. 33(2) PCT)

- a) None of the available documents discloses either a method for the identification of glucose regulated genes comprising the use of suppression subtractive hybridisation or the sequences SEQ ID 1-3, 5 and 6. The subject-matter of claim 1, of claims 2-7 dependent thereon and of claim 11 is thus novel (Art. 33(2) PCT).
- b) In view of the novelty of the said sequences, also claims 8-10, insofar as related thereto, are novel (as to claims 7-10 see also Part VIII hereinbelow).

2) Inventive step (Art. 33(3) PCT)

- a) D1 (BBRC, 179-84, 1997, Holmes et al.) teaches a method for the identification of glucose regulated genes in mesangial cells by mRNA differential display. The method comprises the culturing of the cells in the presence of a high glucose concentration (4 or 30 mM) and the detection of differentially expressed genes by the differential display method (see abstract, materials and methods). Various genes are detected, a few of them previously unknown (see fig. 3 and discussion). Starting from D1, the technical problem to be solved may be defined as that of providing an alternative method for the detection of glucose regulated genes. This problem is solved by the method of claim 1, which comprises the use of suppression subtractive hybridisation (SSH) instead of mRNA differential display (mRNA-DD) as in D1.

By the presently claimed method, the inventors were able to identify previously unknown genes which are glucose regulated.

Although SSH is a known technique (see p. 4, l. 1-14 of the application) there are no indications in any of the available documents that its application to the detection of glucose regulated genes would have lead to the identification of previously unknown genes. In view of this unexpected effect, the subject-matter of claim 1 is deemed to involve an inventive step.

The same applies to claims 2-7 dependent thereon and to claim 11.

- b) Claims 8-10, insofar as related to SEQ ID 1-6, also involve an inventive step since

the said sequences are either novel and inventive (SEQ ID 1-3,5-6) or have never been previously suggested to be linked to diabetic nephropathy (SEQ ID 4).

PART VII

- 1) Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this documents identified therein.

PART VIII

- 1) Claim 7 is unclear (Art. 6 PCT), because the genes detected by the method of claims 1-6 are not a technical feature of the method but merely represent the result of its application.
- 2) Claims 8-10 are not supported by the description (Art. 6 PCT) and their subject-matter contravenes Art. 5 PCT insofar as related to completely uncharacterised genes. SEQ ID 1-6 have been identified by the method of the invention, which is based on an accepted diabetic nephropathy model, and therefore their use as indicated in claims 8-10 can find support.
However, this does not apply to genes solely characterised in that they can be identified by the method of claims 1-7 and for which no further technical features are given in the said claims. The skilled person would not know which genes are covered by the claims and which are not.
Claims 8-10, therefore, should have been limited to clearly characterised genes, i.e. those comprising SEQ ID 1-6.

gene susceptible to such differential expression and identifying the gene so induced by suppression subtractive hybridisation.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

Further, preferably, the concentration of glucose is greater than 5 mM.

10

A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic “*in vitro*” model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20

In one embodiment, the mesangial cells are subjected to mechanical strain.

25 In a further embodiment, transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

AAAATTATTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG
GATTTATTTACTATTATCCACCAGCAACAAGATATCAAAC
ACTGGTCTGTGATTATTAATGGTAAAAAGTTGAATAAAC
5 AATTAGTATACCCATATGTTGGAATTGAGTCCATTTCCTT
TTAAAAATCACACTTGGAAATAATTGATGATACTGGCAAATGC
TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT
AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA
AAAGAAAAAGACTGAAAGGAACCATCCACAATGCTTGATC
10 GGGAAAGACGGAGAAACAAAGTGTAAATTCTTAACTAG
TTTNGGTGTATTCCAGATTTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

2)GTACTTTGGATTGGTTAACCTGTTTCTCAAGCCTGAGGT
15 TTTATATAACAAACTCCCTGAATACTCTTTGCCTGTATCTTC
TCAGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACA
CTGCAGACTTGAGATTAGTTGCCATCAAGGCTCTGGCATTC
AGAGAACCCCTGCAACTCGAGAAGCTGTTTATTCGTTTT
GTTTGATCCAGTGCTCTCCATCTAACAACTAAACAGGAGCC
20 ATTCAAGGCGGGAGATATTAAACACCCAAAATGGTTGGG
TCTGATTTCAAACTTTAAAACCTCACTACTGATGATTCTGCA
CGCTAACCGGAATTGGTCCAAACACATAAGTGTGTGTTT
GTATACACTGTATGACCCCACCCAAATCTTGTATTGTCCAC
ATTCTCC IHG-2 (SEQ ID NO: 4);

25

3)AGAAGCAATTAGGAANCCNACAGNAAANAAATGCTGTTT
ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTGTA

10

GACGATGTTGAATAGGTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTGCTT
AACACCCAACTCCTCCACCCGTGCAGTTNNCTTGCCAGT
GATCACAGGATTCGCTGAGTGAATTACCATAATTGGATTTAAT
5 TCACGAAGGGATGTTTC (IHG-3) (SEQ ID NO: 5); and

4) ATTGATAGAGGCCCTGTTCATGACATTCATGAGTTCAAT
ATGTTGTTCAGCATGTTGTGAGGTGACTCTCAGCCCCCTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCAAGCATGGTTGATCACAGGTACATG
CAGTTTGCGATAGTAAATGTATCATTGTTCTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCATGT
AGGGATAAAACTTAAAGGACAGATGACACATTGGTCATGTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides SEQ ID NOS: 1-3, 5 and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.

20 However, as hereinafter demonstrated IHG-2 was identified as being a formerly unknown part of the gremlin gene. We have found that mesangial cell gremlin mRNA levels are induced by high glucose, cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels are elevated in the renal cortex of rats with streptozotocin-induced diabetic nephropathy *in vivo*. Gremlin expression was observed in parallel with induction of bone morphogenetic protein-2 (BMP-2), a target for gremlin in models of cell differentiation.

25

Fig. 22 is an autoradiograph of gremlin, fibronectin and GAPDH mRNA levels analysed by Northern Blot as described in Example 8;

5 Fig. 23 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage 25 7-11) were maintained in medium (Clonetechs) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

Example 8

Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TGF- β 1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF- β 1 production by mesangial cells *in vitro* and TGF- β 1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF- β 1 neutralising antibody (1 μ g/ml). Treatment of cultures with glucose and anti-TGF- β 1 were as described in Example 1 and Example 4, respectively. To assess the role of TGF- β 1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF- β 1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

20 Initial studies had indicated that TGF- β 1 neutralizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF- β 1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25 The addition of exogenous human recombinant TGF- β 1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TGF- β 1 antibody (data not shown). To further probe the role of TGF- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9

5 High glucose stress induces BMP-2, but not BMP-4 expression in mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, 10 D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial 15 cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH 20 specific primers gave predicted products of 378 bp and 452 bp respectively.

Fig. 24 depicts representative reactions of 4 independent experiments. 10 μ l of each PCR reaction was run on 1 % ethidium 25 bromide stained agarose gels.

Claims: -

1. A method for identifying a gene having a role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a gene susceptible to such differential expression and identifying the gene so induced by suppression subtractive hybridisation.
10
2. A method according to Claim 1, wherein the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the mesangial cells are subjected to mechanical strain.
20
5. A method according to any preceding claim, wherein transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

6. A method according to any one of Claims 1-5, wherein the possibility of differential expression due to hyperosmolarity is excluded.

5 7. A method according to any one of Claims 1-6, wherein the gene so differentially expressed is a gene which includes a sequence selected from:

10 1) SEQ ID NOS: 1-3;

2) SEQ ID NO: 4;

15 3) SEQ ID NO: 5; and

4) SEQ ID NO: 6.

8. Use of a gene identified by a method according to any one of Claims 1-7, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20

9. Use of a gene identified by a method according to any of Claims 1-7, as an index of disease activity and the rate of progression of diabetic nephropathy.

25

10. Use of a gene identified by a method according to any of Claims 1-7, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

11. A sequence selected from any one of SEQ ID NOS: 1-3, 5 and 6 according to Claim 7.

5

ATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P00-18-PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/ IE 00/ 00026	International filing date (<i>day/month/year</i>) 28/02/2000	(Earliest) Priority Date (<i>day/month/year</i>) 26/02/1999
Applicant HIBERGEN LIMITED et al		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
 - contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. **Certain claims were found unsearchable** (See Box I).

3. **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IE 00/00026

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLMES D I ET AL: "Identification of glucose -regulated genes in human mesangial cells by mRNA differential display." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 SEP 8) 238 (1) 179-84. XP000919240 the whole document ---	1-7
A	DATABASE EMSTS 'Online! EMBL, Heidelberg; Accession Number G38490, 24 June 1998 (1998-06-24) MYERS R.M.: "Human STSs 1998" XP002143063 abstract --- -/-	12

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

20 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Luzzatto, E

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IE 00/00026

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE EMEST 'Online! EMBL, Heidelberg; Accession Number AA071138, 4 October 1996 (1996-10-04) HILLIER L. ET AL.: "Generation and analysis of 280000 human expressed sequence tags" XP002143064 abstract ----	12
P, X	MURPHY M ET AL: "Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 FEB 26) 274 (9) 5830-4., XP002142860 the whole document ---	1-7
P, X	DATABASE EMHUM 'Online! EMBL, Heidelberg; Accession Number AK000553, 22 February 2000 (2000-02-22) SUGANO S. ET AL.: "NEDO human cDNA sequencing project" XP002143065 abstract ---	12
P, X	DATABASE GENESEQ 'Online! Derwent; Accession Number Z52443 (WO-A-9957144), 24 February 2000 (2000-02-24) HILLMAN J.L. ET AL.: "New peptides useful for diagnosis, prevention and treatment of cancer and immune disorders" XP002143066 abstract ---	12
X	DATABASE EMEST 'Online! EMBL, Heidelberg; Accession NUmber N52279, 18 February 1996 (1996-02-18) HILLIER L. ET AL.: "The WashU-Merck EST project" XP002143067 abstract -----	12

gene susceptible to such differential expression and identifying the gene so induced.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

Further, preferably, the concentration of glucose is greater than 5 mM.

10 A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic “*in vitro*” model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20 In one embodiment, the mesangial cells are subjected to mechanical strain.

In a further embodiment, transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

25 Preferably, the differentially expressed gene is identified by suppression subtractive hybridisation.

AAAATTATTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG
GATTTATTTACTATTATCCACCAGCAACAAGATATCAAAC
ACTGGTTCTGTGATTATTAATGGTGAAGAAGTTGAATAAAC
5 AATTAGTATAACCATATGTTGGAATATTGAGTCCATTTCTT
TTAAAAATCACACTTGGAATAATTGATGATACTGGCAAATGC
TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT
AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA
AAAGAAAAAGACTGAAAGGAACCATCCACAATGCTTGATC
10 GGGAAAGACGGAGAAACAAAGTGTAACTTCTTAACTAG
TTTNGGTGTATTCCAGATTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

GTACTTGGATTGGTTAACCTGTTCTCAAGCCTGAGGTTT
15 TATATACAAACTCCCTGAATACTCTTTGCCTGTATCTTC
AGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACACT
GCAGACTTGAGATTAGTTGCCGATCAAGGCTCTGGCATT
AGAACCTTGCAACTCGAGAAGCTGTTTATTGTT
TTGATCCAGTGCTCTCCATCTAACAACTAAACAGGAGCCATT
20 TCAAGGCAGGAGATATTAAACACCCAAAATGGTTGGGTCT
GATTTCAAACTTAAAACCTCACTACTGATGATTCTGCACG
CTAAGGCGAATTGGTCCAAACACATAAGTGTGTGTT
ATACACTGTATGACCCCACCCAAATCTTGTATTGTCCACAT
TCTCC (SEQ ID NO: 4);

25

3)AGAAGCAATTAGGAANCCNACAGNAANAAATGCTGTTT
ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTGTA

GACGATGTTGAATAGGTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTGCTT
AACACCCAACTCCTCCACCCTGTGCAGTTNNCTTGTGCCAGT
GATCACAGGATTGCTGAGTGAATTACCATAATTGGATTAAAT
5 TCACGAAGGGATGTTTC (IHG-3) (SEQ ID NO: 5); and

4) ATTGATAGAGGCCCTGTTCATGACATTCATGAGTTCAAT
ATGTTGTTCAGCATGTTGTGAGGTGACTCTCAGCCCCTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCAAGCATGGGTTGATCACAGGTACATG
CAGTTTTGGCATAGTAAATGTATCATTGTTCTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCATGT
AGGGATAAACTTAAAGGACAGATGACACATTGGTCATGTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides genes containing sequences 1-3, 5 and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.

20 However, as hereinafter demonstrated IHG-2 was identified as being a formerly unknown part of the gremlin gene. We have found that mesangial cell gremlin mRNA levels are induced by high glucose, cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels are elevated in the renal cortex of rats with streptozotocin-induced
25 diabetic nephropathy *in vivo*. Gremlin expression was observed in parallel with induction of bone morphogenetic protein-2 (BMP-2), a target for gremlin in models of cell differentiation.

Fig. 22 is an autoradiograph of gremlin, fibronectin and GDAPH mRNA levels analysed by Northern Blot as described in Example 8;

5 Fig. 23 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage 25 7-11) were maintained in medium (Clonetechs) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

Example 8

Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TG-β1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF-β1 production by mesangial cells *in vitro* and TGF-β1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF-β1 neutralising antibody (1 µg/ml). Treatment of cultures with glucose and anti-TGF-β1 were as described in Example 1 and Example 4, respectively. To assess the role of TGF-β1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF-β1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

10

15

20

Initial studies had indicated that TGF-β1 neuturalizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF-β1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25

The addition of exogenous human recombinant TGF-β1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TBF- β 1 antibody (data not shown). To further probe the role of TGB- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9

5 High glucose stress induces BMP-2, but not BMP-4 expression in mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, 10 D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

15 As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH specific primers gave predicted products of 378 bp and 452 bp respectively.

20 Fig. 24 depicts representative reactions of 4 independent experiments. 10uL of each PCR reaction was run on 1 % ethidium bromide stained agarose gels.

Claims: -

1. A method for identifying a gene having a role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a gene susceptible to such differential expression and identifying the gene so induced.
- 10 2. A method according to Claim 1, wherein the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the mesangial cells are subjected to mechanical strain.
- 20 5. A method according to any preceding claim, wherein transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.
- 25 6. A method according to any preceding claim, wherein the differentially expressed gene is identified by suppression subtractive hybridisation.

7. A method according to any one of Claims 1-6, wherein the possibility of differential expression due to hyperosmolarity is excluded.

8. A method according to any one of Claims 1-7, wherein the gene so differentially expressed is a gene which includes a sequence selected from:

1) SEQ ID NOS: 1-3;

10 2) SEQ ID NO: 4;

3) SEQ ID NO: 5; and

4) SEQ ID NO: 6.

15

9. Use of a gene identified by a method according to any one of Claims 1-8, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20 10. Use of a gene identified by a method according to any of Claims 1-8, as an index of disease activity and the rate of progression of diabetic nephropathy.

25 11. Use of a gene identified by a method according to any of Claims 1-8, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

12. A gene containing a sequence selected from any one of sequences 1-3, 5 and 6 according to Claim 8.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68		A1	(11) International Publication Number: WO 00/50637
			(43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/IE00/00026		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 February 2000 (28.02.00)			
(30) Priority Data: 990157 26 February 1999 (26.02.99) IE			
(71) Applicants (<i>for all designated States except US</i>): HIBERGEN LIMITED [IE/IE]; Cork Airport Business Park, Kinsale Road, County Cork (IE). UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN [IE/IE]; Belfield, Dublin 4 (IE).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (<i>for US only</i>): BRADY, Hugh, Redmond [IE/IE]; "Aspen", Violet Hill, Killiney, County Dublin (IE). GODSON, Catherine, Mary [IE/IE]; 12 Yale, Ardilea, Dublin 14 (IE). MARTIN, Finian, Mary [IE/IE]; 104 Mount Anville Road, Goatstown, Dublin 14 (IE).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agent: ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).			

(54) Title: IDENTIFICATION OF GENES HAVING A ROLE IN THE PRESENTATION OF DIABETIC NEPHROPATHY**(57) Abstract**

A method for identifying a gene having a role in the presentation of diabetic nephropathy comprises culturing mesangial cells in the presence of a concentration of glucose sufficient to induce differential expression, especially up-regulation, of a gene susceptible to such differential expression and identifying the gene so induced. The cells are also optionally subjected to mechanical strain and/or TGF- β 1 can be added to the culture medium. The differentially expressed genes can be identified by suppression subtractive hybridisation. The method has resulted in the identification of novel genes which play a role in the presentation of diabetic nephropathy. The genes can be used as diagnostic markers for diabetic nephropathy and as the basis of drug development programmes.

DescriptionIdentification of genes having a role in the presentation of diabetic nephropathy.

5

Technical Field

This invention relates to the characterisation and identification of genes which play a role in diabetes, more particularly in the onset and progression of diabetic nephropathy and to the use of genes so characterised and/or identified as diagnostic markers for diabetic nephropathy and as the basis of drug development programmes.

Background Art

15

Between 2-5% of the population develops diabetes mellitus and 20-30% of diabetics develop diabetic nephropathy. The latter accounts for over 30 % of end-stage renal failure (E.S.R.F.) requiring dialysis or transplantation in western society. The pathological hallmark of diabetic nephropathy is glomerulosclerosis due to accumulation of extracellular matrix proteins in the glomerular mesangium. Mesangial matrix accumulation reflects both increased synthesis and decreased degradation of extracellular matrix (ECM) components, and correlates with the clinical onset of proteinuria, hypertension and progressive kidney failure. Hyperglycaemia is a major stimulus for mesangial cell matrix production in diabetic nephropathy. The mechanisms by which hyperglycaemia perturb mesangial cell function are still being

appreciated and include direct effects of high extracellular glucose levels and indirect effects transduced through alterations in glomerular haemodynamics and through the actions of advanced glycosylation end products.

5

Propagation of mesangial cells under conditions of high ambient glucose has proved a useful *in vitro* model with which to probe the molecular basis for mesangial matrix accumulation in diabetes, attributable to hyperglycaemia. Specifically, exposure of cultured 10 mesangial cells to high glucose stimulates *de novo* synthesis of ECM components, such as type IV collagen, fibronectin and laminin, and other products that are accumulated *in vivo* (Ayo, S.H., *et al.* (1990) *Am.J. Pathol.* 136, 1339-1348; Wahab, N.A., *et al.* (1996) *Biochem. J.* 316, 985-992; and Ayo, S.H., *et al.* (1991) *Am. J. Physiol.* 260, F185-15 F191).

In view of the high morbidity and mortality rate from diabetic nephropathy in diabetics there is a need to identify stimuli which affect the onset and progression of diabetic nephropathy with the aim of preventing such onset or inhibiting or limiting the progression thereof. 20

Disclosure of Invention

The invention provides a method for identifying a gene having a 25 role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a

gene susceptible to such differential expression and identifying the gene so induced.

5 Preferably, the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.

Further, preferably, the concentration of glucose is greater than 5 mM.

10 A concentration of 5 mM falls within the normal range of plasma glucose levels in a healthy human subject (4.2 – 6.4 mmol/l).

15 The concentration of glucose used is suitably in the range 5-30 mM. The concentration of 30 mM was chosen as the classic “*in vitro*” model of diabetic nephropathy which induces changes in mesangial function that mimic human disease. This level is also encountered in many diabetics *in vivo*.

20 In one embodiment, the mesangial cells are subjected to mechanical strain.

In a further embodiment, transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.

25 Preferably, the differentially expressed gene is identified by suppression subtractive hybridisation.

Suppression subtractive hybridisation (SSH) is a method based on suppressive PCR that allows creation of subtracted cDNA libraries for the identification of genes differentially expressed in response to an experimental stimulus (Gurskaya, N.G., *et al.* (1996) *Anal. Biochem.* 240, 90-97). SSH differs from earlier subtractive methods by including a normalisation step that equalises for relative abundance of cDNAs within a target population. This modification should enhance the probability of identifying increased expression of low abundance transcripts, and represents a potential advantage over other methods for identifying differentially regulated genes such as differential display-PCR (DD-PCR) (Liang, P., and Pardee, A.B. (1992) *Science* 257, 967-97) and cDNA-representation difference analysis (Hubank, M., and Schatz, D.G., (1994) *Nucleic Acid Res.* 22, 5640-5648).

15

To date we have used SSH to identify 150 genes differentially induced when human mesangial cells were exposed to high extracellular glucose (defined herein as 30 mM versus 5 mM) *in vitro*. These genes included:

20

(a) known regulators of mesangial cell activation in diabetic nephropathy, namely fibronectin, caldesmon, thrombospondin and plasminogen activator inhibitor-1;

25

(b) novel genes; and

(c) genes whose induction by high glucose has not previously been reported as hereinafter described.

Prominent among the latter were genes encoding cytoskeleton-associated proteins and connective tissue growth factor (CTGF), a modulator of fibroblast matrix production. We have also demonstrated elevated CTGF mRNA levels in glomeruli of rats with streptozotocin-induced diabetic nephropathy.

10 In one aspect of the invention, the possibility of differential expression due to hyperosmolarity is excluded.

Hyperosmolarity is, however, a component of diabetic nephropathy and thus hyperosmolarity may represent a mechanism 15 through which high glucose induces differential expression of certain genes having a role in the presentation of the disease.

For example, we have shown that mannitol provoked less mesangial cell CTGF expression *in vitro* than high glucose, excluding 20 hyperosmolarity as the key stimulus.

High glucose also stimulated expression of transforming growth factor β 1 (TGF- β 1) and addition of TGF- β 1 to mesangial cells triggered CTGF expression. Anti-TGF- β 1 antibody blunted CTGF expression 25 induced by high glucose. Together, these data suggest that (1) high glucose stimulates mesangial CTGF expression by TGF β 1-dependent

and independent pathways, and (2) CTGF may be a mediator of TGF- β 1-driven matrix production within a diabetic milieu.

5 CTGF may therefore be an attractive target for design of novel anti-sclerotic therapies for diabetic glomerulosclerosis.

10 CTGF derived from mesangial cells is a potential stimulus for increased synthesis of ECM proteins and mesangial expansion in diabetic nephropathy. The mechanisms by which high glucose triggers mesangial cell CTGF and, indeed, TGF- β , mRNA expression remain to be defined. Possible upstream triggers of CTGF transcription in response to high glucose include *de novo* synthesis of diacylglycerol (DAG) and subsequent activation of protein kinase C (PKC) (DeRubertis, F.R., and Craven, P., (1994) *Diabetes* 43, 1-8 and Fumo P., 15 *et al.* (1994) *Am. J. Physiol.* 267, F632-F638), non-enzymatic glycation end-products (Brownlee, M., *et al.* (1984) *Ann. Intern. Med.* 101, 527-537 and Cohen, M.P., and Ziyadeh, F.N. (1994) *Kidney Int.* 45, 475-484) increased activity of the polyol pathway and disordered myoinositol metabolism (Goldfarb, S., *et al.* (1991) *Diabetes* 40, 465-471 20 1991) or through the recruitment of locally generated growth factors such as TGF- β 1 and other mediators. (Sharma K., and Ziyadeh, F.N., (1995) *Diabetes* 44, 1139-1146).

25 TGF- β 1 has been implicated as the key mediator of extracellular matrix accumulation in diabetic nephropathy and other chronic renal disease . Several studies have reported increased expression of TGF- β 1 in renal glomeruli in human and experimental models of diabetes (Park,

I., *et al.* (1997) *Diabetes* 46, 473-480; Sharma, K., (1996) *Diabetes* 45, 522-530). Short term administration of TGF- β 1 neutralising antibodies attenuates overexpression of mRNAs encoding matrix components and glomerulosclerosis in the STZ mouse model of diabetes (Park, I., *et al.* 5 (1997) *Diabetes* 46, 473-480). CTGF shares some of the biological actions of TGF- β 1 such as stimulation of cell proliferation and extracellular matrix protein synthesis in fibroblasts. When considered in this context, the results described herein suggest that TGF- β 1 may promote mesangial matrix production, in part, by inducing CTGF 10 synthesis. TGF- β 1 has a complex profile of biological activities that includes pro-inflammatory, pro-fibrotic and anti-inflammatory effects. By targeting CTGF it may be possible to attenuate the sclerosis-inducing effects of TGF- β 1 while preserving its more desirable anti-inflammatory activities.

15

Novel genes identified by the method according to the invention are identified herein as IHG (*Increased in High Glucose*) and DHG (*Down in High Glucose*) and are represented by genes which include the following sequences 1, 3 and 4:

20

1) TTGGAATAGTTCTGCTTATAAAAATAGTACTGCGATTAAA
AAAAAAAGCACTTCTGCCAAAGGAACCATGTTCCAACACCGCA
AACAAAGGTGTTCTGCTTAAACAGAGTAAGATAACACCACCC
ATCCATCCCTTCCTCCCTGTTCCCCTCCCAACTTGAGTTGTGT
25 CATT CGC ACC AGT GT CCT GGG GT GGG TAG GG AT GCT AC AG CC AC
CTAAGGCAAGGAGCCCTGGGAGGTGGGAGGGCTGCATGGTT
AAGCACACCAGAACTGAAGCGAAAAGGGTCAGCTGTCTCA

TCTAGAATCTCTGGATGTTCTTCCAGAAAGCATCCCCATGA
TATCGCAGTGCAAGGGCACTGGCTTGTCTGGTCCGGTCAC
TGCCATTTTCTTCCATTCTGTTGGCAGCTAACATTCTT
TGTCACTCACTCATCCACCTCTGCCATATCAACACAGTCCCTT
5 TCCTATAACATCGGCAGCTCATTATTATAGTTGATGTTGAATT
AGAAAAACAAAATCTCATTCTTGTCTGCTGNAAGAGTTCCCTGT
AATCTCCCTGGGCTTGTACTGGTGTAGTCCAGATTGTTG
(SEQ ID NO: 1)

.....
10GGTCCTTTAA
AGTCTGGTTGCTGGATACACCACGACTCTCCGGTCAAAGCC
TGGGGGATACAGAAGGGGTRGTCTCAAAGTAATCCGCCA
ATAAAACAYATAGCTGGAGGCAAACGGGAGGYCACGTGAGT
CATGAACCTTACTGGCTCTTAAACCAATTGGTTTCCGC
15 TTGWACACAAAGCTGTACTCATCACTCTGTCCATAACGCGAT
CACAATATCCTCTAGTTCTCATCACAGTCTGCGCACATTG
GTCATCAGCTGGAGAGCACGGCTGTCATTGGTTTGC
TGTGCTTCTCAGCAAACCGATGGAAATTCCGGCCGTCCAGCCG
NACTACCACCCAGCAGTGTGCCAGGCAGGTGTCGT
20 CAGCCTCACGTACTCGAACCTGCTTTGCCATGGTCGCC
CCCAATCTCAGGTACCGTCTCAGAGTGATGGAAATGGTGGCC
AAGGAATCGTGAACCTTAACCTTACAGGCGCCCCACATTCTAC
ACGCGGAAAGGAAAGGGCCAGATAGCCCCGCCCCGGAAAGTG
TTCTCTCGTGGCTACTCTAGCCGTAGGGCGGT
25 CTCGSCTCTCCCTGKAGTTCTAACMCYYCCAGGGAAARAGGA
TGGAGGTTAGGTTCCGTTAGCACCTCCACGCTTGCTTCT
TCCTCCTCCGGTCTGCGGCAAATCAGTCTCACGAGGTTTA

AAAATTATTTTATCTGCTGGCCTT (SEQ ID NO: 2)

.....ATGACACAAATATTAG
GATTTATTTACTATTATCCACCAGCAACAAGATATCAAAC
ACTGGTTCTGTGATTATTAATGGTGAAGAAGTTGAATAAAC
5 AATTAGTATAACCATATGTTGAAATATTGAGTCCATTTCTT
TTAAAAATCACACTTGGAAATAATTGATGATACTGGCAAATGC
TCAAGCTGAGTGGAAAAATATATAAACATTGTATAGGCGAAT
AATTCCAATCTTGTGCATTCCCTGTGTAAACCTACATACACAA
AAAGAAAAAGACTGAAAGGAACCATCCACAATGCTTGATC
10 GGGAAAGACGGAGAAACAAAGTGTTAATTTCTTAACTAG
TTTNGGTGTATTCCAGATTTCTACAAGTTAATA (IHG-1) (SEQ
ID NO: 3);

GTACTTGGATTGGTTAACCTGTTCTCAAGCCTGAGGTTT
15 TATATACAAACTCCCTGAATACTCTTTGCCTGTATCTTC
AGCCTCCTAGCCAAGTCCTATGTAATATGGAAAACAAACACT
GCAGACTTGAGATTCAAGTGGCGATCAAGGCTCTGGCATTCA
AGAACCCCTTGCAACTCGAGAAGCTGTTTATTGTTTTGTT
TTGATCCAGTGCTCTCCATCTAACAACTAAACAGGAGGCCATT
20 TCAAGGCGGGAGATATTTAACACCCAAAATGGTTGGGTCT
GATTTCAAACCTTTAAAACCTCACTACTGATGATTCTGCACG
CTAAGGCGAATTGGTCCAAACACATAAGTGTGTGTTTGT
ATACACTGTATGACCCCACCCAAATCTTGTATTGTCCACAT
TCTCC (SEQ ID NO: 4);

25

3)AGAAGCAATTAGGAANCCNACAGNAAANAAATGCTTTT
ATAGGAGAGAAAACACGGCACACCAAGGTTAAGTAGTTGTA

10

GACGATGTTGAATAGGTTCAGGTACAGGTCAATGCAGTGATG
AGGAAAGCACCTANGTATACTTGACAGATAGTCCCCTTGCTT
AACACCCAACCTCCTCCACCCTGTGCAGTTNNCTTGCCAGT
GATCACAGGATTGCTGAGTGAATTACCATATTGGATTTAAT
5 TCACGAAGGGATGTTTC (IHG-3) (SEQ ID NO: 5); and

4)ATTGATAGAGGCCCTGTTCATGACATTGAGTTCAAT
ATGTTGTTCAGCATGTTGTGAGGTGACTCTCAGCCCCTTCCC
ACTGAGATGGACTGTGGTGATGCTGTGAGGGTGTGACTGACA
10 CACCTTCATGTGCCAAGCATGGTTGATCACAGGTACATG
CAGTTTTGGCATAGTAAATGTATCATTGTTCTTCCTCCCTC
CTAAAGGAAACAGAGGAATCCACCTGTATGAGAGTGCATGT
AGGGATAAACTAAAGGACAGATGACACATTGGTCATGTTCG
TGATAAGGAAA (DHG-1) (SEQ ID NO: 6).

15

The invention also provides genes containing sequences 1-3, 5 and 6 set out above.

In initial studies the gene IHG-2 was assumed to be new.

20 However, as hereinafter demonstrated IHG-2 was identified as being a formerly unknown part of the gremlin gene. We have found that mesangial cell gremlin mRNA levels are induced by high glucose, cyclic mechanical strain and TGF- β 1 *in vitro*, and gremlin mRNA levels are elevated in the renal cortex of rats with streptozotocin-induced
25 diabetic nephropathy *in vivo*. Gremlin expression was observed in parallel with induction of bone morphogenetic protein-2 (BMP-2), a target for gremlin in models of cell differentiation.

Gremlin, together with DAN and cerberus, are members of the cysteine knot super-family of proteins that have recently been shown to play important roles in limb development and neural crest cell differentiation (Hsu, D.R., *et al.* (1998) *Mol. Cell.* 1, 673-83; Zuniga, A., *et al.* (1999) *Nature* 401, 598-602). Of potential interest in the context of diabetic nephropathy, gremlin is a putative inhibitor of BMP-2 in models of neural crest cell differentiation. BMP-2 has recently been reported to have antiproliferative effects on mesangial cells.

The following Examples show that (a) IHG-2 is part of gremlin, (b) gremlin is expressed in diabetic nephropathy *in vivo*, (c) both glycemic and mechanical strain stimulate mesangial cell gremlin expression *in vitro*, (d) high glucose induces gremlin, in part, through TGF β -mediated pathways, and (e) gremlin is a potential endogenous antagonist of BMPs within a diabetic glomerular milieu.

The invention also provides use of a gene identified by the method according to the invention:

- 1) as a diagnostic marker for the progression and presentation of diabetic nephropathy;
- 2) as an index of disease activity and the rate of progression of diabetic nephropathy; and

3) as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

Thus, it will be appreciated that early diagnosis of diabetic
5 nephropathy based on diagnostic markers identified in accordance with the invention can be used in conjunction with aggressive therapies to prevent full blown development of diabetic nephropathy.

The level of expression of genes identified in accordance with
10 the invention could correlate with the degree of disease progression.

Furthermore, genes identified in accordance with the invention can represent novel therapeutic targets for drug development programmes. Once it has been established that a given gene has a
15 designated role in the pathophysiology of diabetic nephropathy, the development of new therapeutic agents (such as, for example, small molecules, recombinant inhibitors and receptor antagonists) could be designed to inhibit expression of these genes and, thereby, prevent the development of diabetic nephropathy.

20 Genes identified in accordance with the invention can also be used as a clinical index of progressive renal sclerosis and scarring, as a guide to the response of progressive diabetic nephropathy to therapy and also as markers of the prevention or development thereof.

25 It is possible to generate mouse knock-out (k/o) models for genes identified in accordance with the invention and to generate

diabetic k/o mouse models, (for example by treatment with streptozotocin) and determine if onset of diabetic nephropathy is inhibited, reduced or delayed. Thus one can determine if a given knock-out gene has a definite role in the progression and development of
5 diabetic nephropathy.

Brief Description of Drawings

Fig. 1 is an autoradiograph of CTGF levels analysed by Northern Blot as described in Example 2;

Fig. 2 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 2;

Fig. 3 is a 2 % agarose gel showing ethidium-stained PCR products as described in Example 2;

Fig. 4 is a nucleotide sequence alignment of the rat CTGF transcript and the mouse CTGF homologue fisp 12 as described in Example 3;

Fig. 5 is an amino acid sequence alignment of the rat CTGF transcript and the mouse CTGF homologue fisp 12 as described in Example 3;

Fig. 6 is a 2 % agarose gel showing ethidium-stained PCR products as described in Example 3;

Fig. 7 is an autoradiograph of CTGF levels in the presence of TGF- β 1 and TGF- β 1 neutralising antibodies analysed by Northern Blot as described in Example 4;

5

Fig. 8 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;

10 Fig. 9 is an autoradiograph of CTGF levels in the presence of varying amounts of glucose and TGF- β 1 neutralising antibodies analysed by Northern Blot as described in Example 4;

15 Fig. 10 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;

Fig. 11 is an autoradiograph of CTGF levels in the presence of varying amounts of glucose and PKC inhibitor GF102903X analysed by Northern Blot as described in Example 4;

20 Fig. 12 is a graph of the relative amount of CTGF mRNA as estimated by Phosphor Imager quantification as described in Example 4;

25 Fig. 13 is a graphical representation of a BLAST output from the EST database as described in Example 6;

Fig. 14 is a graphical representation of the alignment of human gremlin and rat drm when compared using the BLAST algorithm as described in Example 6;

5 Fig. 15 is the sequence of mesangial cell gremlin cDNA;

Fig. 16 is an autoradiograph of IHG-2, gremlin, fibronectin and GAPDH mRNA levels analysed by Northern Blot as described in Example 7;

10 Fig. 17 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

15 Fig. 18 is an autoradiograph of gremlin, fibronectin and GAPDH mRNA analysed by Northern Blot as described in Example 7;

Fig. 19 is a further graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

20 Fig. 20 is an autoradiograph of gremlin mRNA levels in the kidney cortex of a STZ-diabetic rat and an age matched control analysed by Northern Blot as described in Example 7;

25 Fig. 21 is a further graph of relative mRNA levels as estimated by Phosphor Imager quantification as described in Example 7;

Fig. 22 is an autoradiograph of gremlin, fibronectin and GDAPH mRNA levels analysed by Northern Blot as described in Example 8;

5 Fig. 23 is a graph of relative mRNA levels as estimated by Phosphor Imager quantification; and

Fig. 24 is a graphical representation of representative reactions of four independent experiments as described in Example 9.

10 The invention will be further illustrated by the following Examples:

Modes for Carrying Out the Invention

15 Example 1

Identification of mesangial cell genes differentially induced by high glucose.

20 a) Cell culture and streptozotocin-induced diabetic rats

Primary human mesangial cells were cultured as previously reported (Brady, H.R., *et al.* (1992) *Kidney Int.* 42, 480-487 and Denton, M.D., *et al.* (1991) *Am. J. Physiol.* 261, F1071-F1079). Cells (passage 25 7-11) were maintained in medium (Clonetics) containing either 5 mM or 30 mM D-glucose for 7 days. Culture medium was replenished three times during this period to maintain glucose levels in the desired range. To control for the effects of hyperosmolarity, mesangial cells were

cultured in media containing 5 mM glucose supplemented with 25 mM mannitol.

Male Munich-Wistar rats (260-290 g, Simonsen Laboratories)
5 were rendered diabetic by treatment with streptozotocin (STZ; Sigma),
50 g/kg, intravenously as described previously (Zatz, R., *et al.* (1985).
Proc. Natl. Acad. Sci. USA. 82, 5963-5967). At months 2 and 4 after
induction of diabetic nephropathy (DN), rats were anaesthetized with
intraperitoneal injection of pentobarbital (50 mg/kg), and the right
10 kidney was excised and weighed immediately. Glomeruli were isolated
from renal cortex by the standard sieving method (Brady, H.R. *et al.*
(1992) and Denton, M.D. *et al.* (1991) *supra*). Glomerular isolation was
completed within 20 minutes of removing the kidney. RNA extraction
proceeded immediately thereafter.

15

b) RNA isolation

Polyadenylated RNA was isolated from mesangial cells using
the Microfast Track (Microfast Track is a Trade Mark) kit (Invitrogen).
20 Total RNA was isolated from glomeruli using RNazol solution (TEL-
test Inc.).

c) Suppression subtractive hybridisation (SSH)

25 SSH was performed with the PCR-SELECT cDNA subtraction
kit (Clontech) as directed by the manufacturer with the modification that
a four-fold greater than recommended amount of driver cDNA was

added to the second hybridisation. Starting material consisted of 2 µg of mesangial cell mRNA cultured in 30 mM D-glucose for 7 days as “tester” and 2 µg of mesangial cell mRNA cultured in 5 mM D-glucose for 7 days as “driver”. Thirty primary PCR cycles and 12 secondary
5 PCR cycles were performed.

d) Cloning and sequencing of cDNAs

PCR products generated by SSH were subcloned into the PCR
10 2.1 vector using the original TA cloning kit (Invitrogen). Subcloned cDNAs were isolated by colony PCR amplification. Sequencing was performed using an automated ABI 370A DNA sequencing system. Sequence reactions were carried out with the ABI prism dye terminator cycle sequencing ready reaction kit (Perkin Elmer). The sequences
15 obtained were compared against GenBank/EMBL and Expressed Sequence Tag (EST) databases using BLAST searches.

SSH analysis suggested differential induction of 16 mRNAs in primary cultures of human mesangial cells propagated for 7 days in 30
20 mM glucose. Northern Blots performed using formaldehyde denaturation according to standard protocols and quantitated using a Phosphor Imager (Biorad) confirmed differential expression of fifteen of the sixteen subcloned fragments as indicated in Table 1.

25 In Table 1 ^a refers to the sequence identity based on comparisons with the Genbank/EMBL database;

b refers to an estimate of the size (kb) of the mRNA identified by Northern Blot analysis; and

c refers to the differential expression of each gene based on

- 5 Northern Blot analysis of primary human mesangial cells cultured under indicated conditions relative to expression in cells cultured in 5 mM glucose. Values were obtained by Phosphor-Imaging and were normalised by comparison with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (*, detected in mesangial cells cultured in 5
10 mM glucose + 25 mM mannitol and 30 mM glucose, but not in 5 mM glucose, fold expression is degree of expression relative to that found in 5 mM glucose).

Table 1

Summary of cDNAs identified by SSH as being induced in mesangial
cells cultured in high glucose.

5

<u>Gene^a</u>	<u>mRNAkb^b</u>	<u>Differential Expression^c</u>		
		<i>30mM glucose</i>	<i>25mM mannitol + 5mM glucose</i>	
<i>Extracellular Matrix Proteins</i>				
Fibronectin	7.0	2.1-fold	1.5-fold	
Thrombospondin	6.0	7.0-fold	8.0-fold	
<i>Actin-Binding Proteins</i>				
MRLC	0.9	3.9-fold	1.6-fold	
T-plastin	1.2	4.2-fold	1.8-fold	
Caldesmon	3.6	3.3-fold	2.8-fold	
Profilin	1.0	2.2-fold	2.3-fold	
CAP	2.6	1.5-fold	1.7-fold	
ARP3	2.5	2.0-fold	1.0-fold	
<i>Growth Factors</i>				
CTGF	2.4	3.0-fold	1.5-fold	
<i>Others</i>				
PAI-1	2.0	1.2-fold	1.0-fold	
	3.0	3.9-fold	2.0-fold	
RBM3	1.5	1.8-fold	1.4-fold	
Ubiquitin	3.0	2.3-fold	1.7-fold	
TCTP	0.8	4.3-fold	2.5-fold	
IHG-1	3.4	*	*	
IHG-2	2.5	2.0-fold	2.0-fold	

Sequence analysis revealed induction of four genes implicated previously in the pathogenesis of diabetic nephropathy: fibronectin, caldesmon, PAI-1, and thrombospondin. Of eleven other cDNA fragments, one encoded a novel gene, designated herein as IHG-1 and ten encoded known genes, including IHG-2 as hereinafter described, whose induction by high glucose had not been reported previously.

Prominent among the latter genes were connective tissue growth factor (CTGF) and several cytoskeleton-associated proteins, namely profilin, caldesmon, adenyl cyclase-associated protein (CAP), actin-related protein-3 (ARP3), T-plastin, and myosin regulatory light chain (MRLC). Subsequent studies focused on induction of CTGF, a regulator of matrix production in several model systems as described in Examples 2 and 3. The prominence of genes encoding multiple actin-binding proteins is also noteworthy, given recent reports implicating F-actin disassembly in the pathogenesis of mesangial cell dysfunction and glomerular hypertension in diabetic nephropathy (Zhou, X., *et al.* (1995) *Lab. Invest.* 73, 372-383 and Zhou, X. Lai, *et al.* (1997) *Kidney Int.* 51, 1797-1808). The induction of profilin expression is particularly interesting given its role as a regulator of actin polymerization under conditions of cell stress (Sohn, R.H. and Goldschmidt-Clermont, P.J. (1994) *Bioessays* 16, 465-472).

Within a diabetic milieu, high glucose levels may perturb cellular function through glucose-specific actions or by increasing the osmolarity of extracellular fluids. The role of hyperosmolarity as a mediator of gene induction by high glucose was assessed by comparing mRNA levels, as determined by Northern Blot, in cells cultured in either

30 mM glucose or in 5 mM glucose supplemented with 25 mM mannitol. High glucose was more effective than high osmolarity at inducing expression of CTGF, myosin regulatory light chain (MRLC), actin related protein 3 (ARP3), T-plastin and translationally controlled tumor protein (TCTP). High glucose and mannitol-induced hyperosmolarity afforded equivalent induction of the other products.

Example 2

10 CTGF expression in mesangial cells cultured in high glucose.

a) Influence of high ambient glucose on CTGF mRNA levels in human mesangial cells.

15 CTGF, is a 38kD cysteine-rich secreted peptide known to modulate ECM production in some extrarenal cell types. In Example 1, SSH analysis identified a cDNA fragment of 250 bp which was identical to bases 814-1061 of the human CTGF cDNA. Induction of CTGF mRNA expression in primary human mesangial cells cultured in high glucose was investigated by Northern Blotting as shown in Fig. 1.

20 In Fig. 1 the lanes represent the following:

Lane 1: RNA from mesangial cells exposed to 5 mM glucose;

25 Lane 2: RNA from mesangial cells exposed to 5 mM glucose and 25 mM mannitol;

Lane 3: RNA from mesangial cells exposed to 30 mM glucose for seven days.

5 A 2.4 kb band was detected following hybridisation with the CTGF probe. The relative amounts of CTGF mRNA as estimated by Phosphor Imager quantification are indicated in Fig. 2. All of the values were normalised to GAPDH levels and the results are representative of three independent experiments.

10

The results indicate that CTGF mRNA expression was between 2.5-3.3-fold higher in mesangial cells cultured in 30 mM glucose as compared with 5 mM glucose.

15

b) Effect of CTGF on mesangial cell matrix production.

20

To investigate the direct effects of CTGF up-regulation on matrix production, in particular the effect on collagens I and IV and fibronectin, mesangial cells were incubated with recombinant CTGF protein.

25

Mesangial cells were serum starved for 24 hr in RPMI 1640 medium supplemented with 0.5 % fetal bovine serum (FBS) and then exposed to rhCTGF (8 ng/ml) (a generous gift from Dr. Gary Grotendorst) for 24 hr (Kreisberg, J.I. and Ayo, S.H. (1993). *Kidney Int.* 43, 109-113). Total RNA was extracted and chromosomal DNA was removed using DNase 1 (Gibco-BRL). Equal amounts of cDNA were

subsequently amplified by PCR using specific primers for GAPDH

(Gen/EMBL accession no. AJ005371, sense:

ACACACAGTCCATGCCATCAC (SEQ ID NO: 7); antisense:

TCCACCACCCTGTTGCTGTA (SEQ ID NO: 8), Collagen I

5 (Gen/EMBL accession no. X55525, sense:

GGTCTTCCTGGCTTAAAGGG (SEQ ID NO: 9); antisense:

GCTGGTCAGCCCTGTAGAAG (SEQ ID NO: 10)), Collagen IV

(Gen/EMBL accession no. M11315, sense:

CCAGGAGTTCCAGGATTCA (SEQ ID NO: 11); antisense:

10 TTTGGTCCCAGAAGGACAC (SEQ ID NO: 12) and fibronectin

(Gen/EMBL accession no. X02761, sense:

CGAAATCACAGCCAGTAG (SEQ ID NO. 13), antisense:

ATCACATCCACACGGTAG (SEQ ID NO: 14)).

15 Fig. 3 depicts ethidium-stained panels of a 2% (w/v) agarose gel containing 10 µl of each PCR reaction after electrophoresis.

In Fig. 3 the lanes represent the following:

20 Lane 1: RT-PCR products from mesangial cells cultured in RPMI 1640 and 0.5% FBS;

Lane 2: RT-PCR products from mesangial cells exposed to rhCTGF (8 ng/ml) for 24 hr.

These results indicate that rhCTGF up-regulates mesangial cell collagens I and IV and fibronectin. These proteins typify matrix accumulation as seen in diabetic nephropathy.

5 CTGF is a member of a small family of highly homologous proteins termed the CCN family (for CTGF / fisp-12, cef10/cyr61 and Nov) (Bork, P (1993). *FEBS Letts.* 327, 125-130.). These peptides are characterised by conservation of 38 cysteine residues that constitute more than 10 % of the amino acid content. All members have signal
10 peptides and appear to be secreted *via* orthodox secretory pathways (Bradham, D.M., (1991) *J. Cell. Biol.* 114, 1285-1294). In the context of diabetic nephropathy, it is intriguing that CTGF which is up-regulated in the presence of ambient glucose, in turn, up-regulates the production of extracellular matrix (ECM). These data demonstrate the potential of
15 CTGF as a stimulus for increased ECM synthesis and mesangial expansion in diabetic nephropathy.

Example 3

20 Enhanced CTGF expression in renal cortex and isolated glomeruli of rats with STZ-induced diabetic nephropathy.

25 To assess CTGF expression in diabetic nephropathy *in vivo*, CTGF mRNA levels were measured in RNA isolated from the cortex of rats with STZ-induced diabetes mellitus. To this end, PCR primers for rat CTGF were designed from the sequence of the mouse CTGF homologue, fisp12 (Genbank/EMBL accession no. M70642, sense:

CTAAGACCTGTGGAATGGGC (SEQ ID NO: 15); antisense:
CTCAAAGATGTCATTGTCCCC (SEQ ID NO: 16)) (Ryseck, R.P.,
(1991) *Cell Growth Differ.* 2, 225-233).

- 5 RT-PCR was performed on total RNA extracted from renal cortex of STZ-diabetic rats and age matched controls. The sequence of the rat CTGF transcript was 94 % identical at the nucleotide level (Fig. 4) and 99 % identical at the amino acid level (Fig. 5) to the mouse CTGF homologue fisp12 (bases 783-1123, accession no. M70642).
10 Nucleotides that differ between the two species are given in upper case and the single different amino acid is in bold.

15 Induction of CTGF mRNA was observed in the renal cortex of rats with STZ-induced diabetic nephropathy at four months after administration of STZ, coincident with mesangial expansion and proteinuria as shown in Fig. 6 and data not shown.

20 Fig. 6 depicts ethidium-stained panels of a 2 % (w/v) agarose gel containing 10 µl of each PCR reaction after electrophoresis. CTGF and GAPDH mRNA levels were analysed in total RNA purified from 2 diabetic animals with established nephropathy after four months of diabetes (lanes 1 and 2) and two age matched control animals (lanes 3 and 4).

25 CTGF expression was further localized to glomeruli by RT-PCR analysis of RNA extracted from glomeruli isolated by differential sieving from the renal cortex of rats with STZ-induced diabetic

nephropathy. Glomerular levels of CTGF mRNA were increased by 2.5-fold and 1.6-fold after two months and four months of diabetes, respectively, by comparison with age and sex-matched controls. The significance of these observations is further supported by a recent report
5 demonstrating CTGF expression in a screen of human renal diseases including diabetic nephropathy (Ito, Y., *et al.* (1998) *Kidney Int.* 53, 853-861).

Example 4

10 Induction of mesangial cell CTGF expression by high glucose involves
TGF- β 1 dependent and independent pathways.

15 It has been shown that TGF- β 1 is a stimulus for mesangial matrix accumulation in diabetic nephropathy. In our experimental model as described in Example 1, high glucose concentrations provoked induction of TGF- β 1 mRNA expression in cultured human mesangial cells over the same temporal framework as CTGF expression (data not shown).

20 To assess the role of TGF- β 1 as a stimulus for CTGF expression in response to high glucose, cells were incubated in either 5 mM glucose or 30 mM glucose plus 1 μ l/ml anti-TGF- β 1 antibody for seven days with three changes of medium. Cells were serum starved for 24 hr in RPMI 1640 and 0.5% FBS. 10 ng/ml TGF- β 1 (Calbiochem) or 10 ng/ml TGF- β 1 preadsorbed with 1 μ g/ml neutralising anti-TGF- β 1 polyclonal antibody were subsequently added for 24 hr.
25

The role of PKC on CTGF expression in response to high glucose was investigated by culturing the mesangial cells in either 5 mM, 30 mM glucose or 30 mM glucose and the PKC inhibitor GF 102903X.

5

Fig. 7 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 hr in the presence (lane 3) and absence (lane 2) of anti-TGF- β 1 neutralising antibody (1 μ g/ml).

10 Cells cultured in RPMI 1640 and 0.5 % FBS for 24 hr served as control (lane 1). A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and reprobed with GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 8). Values were normalised to GAPDH levels and 15 the results are representative of two independent experiments.

20 These results indicate that TGF- β 1 is a potent inducer of increased CTGF mRNA levels under these conditions. This effect was inhibited by the addition of a neutralising anti-TGF- β 1 antibody as depicted in Fig. 7.

25 Fig. 9 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to 5 mM glucose (lane 1), 30 mM glucose (lane 2) and 30 mM glucose in the presence of anti-TGF- β 1 neutralising antibodies (1 μ g/ml) (lane 3) for seven days. A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and probed with

GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 10). Values were normalised to GAPDH levels.

5 The neutralising anti-TGF- β 1 antibody partially attenuated the glucose-induced increase in CTGF transcript level in mesangial cells grown in 30 mM glucose for 7 days (Fig. 9), suggesting that high glucose triggers mesangial cell CTGF expression through TGF- β 1-dependent and independent pathways.

10 Fig. 11 is an autoradiograph of CTGF mRNA levels analysed by Northern Blot and depicts the results obtained when mesangial cells were exposed to 5 mM glucose (lane 1), 30 mM glucose (lane 2) and 30 mM glucose in PKC inhibitor GF102903X (10 μ M) (lane 3) for four
15 days. A 2.4 kb band was detected following hybridisation to the CTGF probe. The blot was stripped and probed with GAPDH. The relative amount of CTGF mRNA as estimated by Phosphor Imager quantification (Fig. 12). Values were normalised to GAPDH levels.

20 Whereas the PKC inhibitor GF102903X was without effect on TGF- β 1-induced CTGF expression in our system (data not shown), this compound afforded partial inhibition of high glucose-induced CTGF expression (Fig. 11).

25 CTGF shares some of the biological actions of TGF- β 1 such as stimulation of cell proliferation and extracellular matrix protein synthesis in fibroblasts. When considered in this context, our results

suggest that TGF- β 1 may promote mesangial matrix production, in part, by inducing CTGF synthesis. TGF- β 1 has a complex profile of biological activities that includes pro-inflammatory, pro-fibrotic and anti-inflammatory effects. By targeting CTGF it may be possible to
5 attenuate the sclerosis-inducing effects of TGF- β 1 while preserving its more desirable anti-inflammatory activities.

Example 5

10

Further characterisation of IHG-2

IHG-2 is a mesangial cell gene which we have identified as being induced in human mesangial cells by high extracellular glucose as described in Example 1. To further characterise this gene, IHG-2 was
15 searched against the dbEST using the BLAST algorithm. This search identified a clone that was 94 % identical to ESTAA071138, clone no: 530117 3'. The sequence for the 5' end of this clone was also in the database, which again identified multiple ESTs. These ESTs showed homology with the 3' untranslated region (UTR) of a rat cDNA clone known as drm/Gremlin. As indicated above, gremlin/drm, together with
20 DAN and cerberus, are members of the cysteine knot super-family which includes TGF β and bone morphogenetic protein (BMP). A second EST W48852, clone no:324951 3', was identified from the IHG-2 BLAST. The 5' end of this clone, EST W48619, was also searched
25 against the database, from which EST AA373348 was obtained. This clone showed homology with the drm 3' UTR, approximately 500 bp from the open reading frame (ORF). Thus, it was possible to make a

direct link from IHG-2 to within 500 bp of the ORF of drm/gremlin. Therefore, by establishing a link between EST AA37348 and the ORF of drm/gremlin, it was confirmed that IHG-2 is part of the 3' UTR of this gene. Primers were designed to recognise the ORF, IHG-2, and the EST 5 clone AA373348. An initial PCR using primers corresponding to the start site of the gremlin/drm gene together with a primer within the IHG-2 clone would give a predicted product of approximately 2.5 kb. This product was nested with primers corresponding to the 3' end of the ORF of gremlin and the EST clone AA373348, generating a product of 10 approximately 500 bp, thus verifying that this EST is in the UTR of the human drm/gremlin gene. Therefore, IHG-2 was found to be part of the drm/gremlin gene, which was not previously known (Fig. 13).

Example 6

15

Use of cloning *in-silico* coupled with PCR to demonstrate that IHG-2 is part of the 3' untranslated region of gremlin

In Example 5 we describe the identification of a transcript, IHG-2, the 20 sequence of which did not show homology against the cumulative database of characterised sequences using the BLAST algorithm.

Bioinformatic analysis was carried out as follows:

25

Database searching and alignments were performed at the National Center for Biotechnology Information (NCBI) Bethesda, Maryland, U.S.A. using the Basic Local Alignment Search Tool

Algorithm (BLAST) (Altschul, S.F., *et al.* (1997) *Nucleic Acids Res.* 25, 3389-3402). The Non Redundant (nr) and the Expressed Sequence Tag (EST) databases were sourced. Contiguous sequences were generated using Fragment Assembly, a program within the Genetics Computer Group Inc. package. UniBlast (Guffanti, A., and Simon, G., *Trends in Genetics*, 14, 293) was used to identify homologous clusters within the UniGene database and to verify the consensus sequence derived from ESTs. Chromosomal localization data were obtained from the UniGene and Online Mendelian Inheritance in Man (OMIM) databases.

10

To further characterise the sequence, the sequence of IHG was searched against the EST database where a number of matches were obtained. Each of these matches was, in turn, searched against the nr database at NCBI. Four ESTs, namely W52686, N28395, H80042, and 15 W47324, showed low homology to the 3' UT region of the rat gene drm referred to in Example 5. The ORF of the human homologue of this gene, gremlin, was also in the database.

15

To generate a link between the ORF of gremlin and IHG-2, successive BLAST searches were used to identify overlapping sequences in the EST database.

20

However, it was not possible to directly link IHG-2 to the ORF of gremlin with sequences within the EST database. Therefore, RNA 25 isolated from human mesangial cells was reverse transcribed with a primer that recognises IHG-2. PCR analyses were performed spanning the regions shown in Fig. 13.

In this graphical representation of a BLAST output from the EST database, the thick bar of 4 kb represents the final composite sequence of the gremlin gene. Each of the other bars represents an individual sequence, in the EST database, that were assembled, where possible, into continuous sequences, and demonstrates how cloning *in-silico* was used to generate the contiguous sequence. The region of no EST overlap was generated by reverse transcription of human mesangial mRNA with a complementary primer to IHG-2. PCR was performed spanning the regions indicated (by arrows), and the resulting products were sequenced, allowing a contiguous cDNA of 4049 bp to be generated which included the open reading frame of gremlin and IHG-2.

Human gremlin and rat drm cDNAs were compared and Fig. 14 shows a graphical representation of an alignment between rat drm and human gremlin together with the region corresponding to IHG-2 using the BLAST algorithm. Sequence homology was found to be high in the coding region of the cDNA; however, there are only small regions of homology within the 3' UT region. This explains why IHG-2 did not identify drm in a BLAST search, but a match to drm, and thus gremlin, was obtained by examining EST sequences further. The lack of homology between rat drm and human gremlin probably results from decreased selective pressure on the 3' UT region of gene homologues to remain the same between species.

25

Fig. 15 shows the final sequence of human mesangial cell gremlin, indicating the ORF and the region corresponding to IHG-2

(GenBank accession no: AF110137). Shown are the 5' and 3' UT sequence, and the open reading frame (with translation). The boxed region corresponds to the location of IHG-2. At the time of submission, this sequence matched 136 separate EST entries in the EST database. Of 5 these entries, 23.5% were derived from fibroblast libraries; 30% were from bone tissue libraries; and 34% were derived from tumor related libraries. The sequence was also searched against the UniGene database using the UniBlast program. This identified 4 UniGene clusters, Hs.214148, Hs.40098, Hs.114330, and Hs.239507. Two of these 10 clusters, Hs.40098, and Hs.239507, have been mapped to intervals D15S118-144 and D15S144-165 on chromosome 15, respectively. Secretory granule neuroendocrine protein 1 and the alpha polypeptide of the nicotinic cholinergic receptor have been mapped to either side of these clusters and have also been mapped more specifically to the 15q11-15 interval. Analysis of the OMIM database reveals that the 15 formin gene, which was recently shown to induce gremlin expression in the developing limb bud (Zuniga, A., *et al.* (1999) *supra*), is also localised to this interval. Diabetes mellitus with multiple epiphyseal dysplasia, or Wolcott-Rallison syndrome, is localised to the 15q11-12 20 interval (Stewart, F.J., *et al.*, (1996) *Clin.Genet.* 49, 152-5). In the epiphyseal growth plate, immunohistochemical studies have revealed that BMP-2 and 4 are expressed in proliferating and maturing chondrocytes, suggesting that BMP and its receptors play roles in the multi-step cascade of enchondral ossification (Yazaki, Y., *et al.*, (1998) 25 *Anticancer Res.* 18, 2339-44). Regulation of gremlin expression may have implications in both of the disease states associated with Wolcott-Rallison syndrome.

Example 7Induction of mesangial cell gremlin expression *in vitro* by high glucose
5 and cyclic mechanical strain induce

A) Primary cultures of human mesangial cells were propagated as described in Example 1, except that the medium was supplemented with 5% FBS. Treatment of cultures with glucose was carried out as 10 described in Example 1. Mesangial cells were exposed to either 5m M glucose or 30mM glucose for seven days.

Northern Blot analysis as described further below was performed on RNA extracted from mesangial cells grown in either 5 mM 15 ('normal') or 30 mM ('high') glucose using the ORF of gremlin and IHG-2 probes. Both probes detected a 2-fold increase in gene expression under high glucose conditions as depicted in Fig. 16.

All subsequent northern analysis was performed using the ORF of 20 gremlin as a probe.

Northern Blots were performed using formaldehyde denaturation according to standard protocols and quantitated using a phosphorimager (Biorad). PCR products used to generate the probes for northern 25 analysis were amplified using primers for the open reading frame (ORF) of gremlin (sense: ATGAGCCGCACAGCCTACAC (SEQ ID NO: 17); antisense TTAATCCAAATCGATGGATATGC (SEQ ID NO: 18)), and

for IHG-2 (sense: CTCAGCCTCCTAGCCAAGTCC (SEQ ID NO 19); antisense: GTATTGTCCACATTCTCCAAC (SEQ ID NO: 20)).

Fibronectin and GAPDH probes were generated as described in Example 2

5 Specific primers were used to amplify gremlin/IHG-2 (external sense: ATGAGCCGCACAGCCTACAC (SEQ ID NO: 21); external antisense: GTATTGTCCACATTCTCCAAC (SEQ ID NO: 22); internal sense: GAGAGTCACACGTGTGAAGC (SEQ ID NO: 23); internal antisense: AGGAGGATGCAAGCACAGG (SEQ ID NO: 24), BMP-2 (external
10 sense: CGCGGATCCTGCTTCTTAGACGGACTGCG (SEQ ID NO: 25); external antisense: TTTGCTGTACTAGCGACACC (SEQ ID NO: 26); internal sense: CAAGATGAACACAGCTGG (SEQ ID NO 27)), and GCTCAGGATACTCAAGAC (SEQ ID NO: 28)). RT-PCR was carried out as reported as described in Example 3.

15

The results are shown in Figs. 16 and 17.

In Figs. 16 and 17, lane 1 corresponds to the mesangial cells exposed to 5 mM glucose and lane 2 corresponds to the mesangial cells
20 exposed to 30 mM glucose.

Fig. 16 is an autoradiograph of IHG-2 (1), gremlin (2), fibronectin (3) and GAPDH (4) mRNA levels analysed by Northern Blot. Two bands of approximately 4.4 kb and 4.6 kb were detected
25 following hybridisation to the gremlin and IHG-2 probes.

Fig. 17 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels. The results are representative of three independent experiments.

5 B) Glomerular hypertension is an independent risk factor for the development of glomerulosclerosis in diabetes mellitus (Brenner, B.M., et al. (1982) *N. Engl. J. Med.* 307, 652-9). To model the effects of glomerular hypertension on mesangial cell gremlin expression in the present study, mesangial cells were propagated under conditions of
10 cyclic mechanical strain for 24 and 48 h in the Flexercell™ System

For the application of mechanical cyclic stretch, primary human mesangial cells were seeded on either flexible or rigid based, elastin coated six-well plates (Flex I and Flex II plates, Flex Cell™ Int, Hillsborough, NH, USA). Cells were grown to 90% confluence, then serum restricted in Clonetics™ Mesangial Basal Medium supplemented with 0.5% fetal calf serum. Cells cultured on flexible plates were subjected to repeated cycles of computer-controlled, vacuum-driven mechanical stretch and relaxation using the Flexercell Strain Unit FX-
20 2000 (Flexercell™). Cells were alternately stretched and relaxed at 0.5 sec intervals (60 cycles/min) for either 24 or 48 h. The applied vacuum achieved a 17% elongation of the outer annulus of the culture plates. All experiments were carried out at 37°C and 5% CO₂ in a humidified incubator.

The results were obtained from three diabetic rats, 14 weeks following onset of diabetes and from three age matched controls.

5 The model used perturbs mesangial cell matrix production and metabolism in a manner similar to that observed in diabetic glomerulosclerosis *in vivo*. Mesangial cell gremlin mRNA levels were significantly enhanced under conditions of mechanical strain, in parallel with increased fibronectin mRNA expression as shown in Figs. 18 and 19.

10

Referring to Figs. 18 and 19 mesangial cells in culture were grown under static conditions (lane 1) or during exposure to cyclic stretch for 24 h (lane 2) or 48 h (lane 3) using the Flexercell TM System.

15

Fig. 18 is an autoradiograph of gremlin(1), fibronectin(2) and GAPDH(3) mRNA analysed by Northern Blot.

In Fig. 18 the lanes represent the following:

20 Lane 1: Mesangial cells grown in culture under static conditions;
Lane 2: Mesangial cells grown in culture during exposure to cyclic stretch for 24 h; and
Lane 3: Mesangial cells grown in culture during exposure to cyclic stretch for 48 h.

25

Fig. 19 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

To assess gremlin expression in diabetic nephropathy *in vivo*, gremlin mRNA levels were measured by Northern Blot analysis with RNA isolated from the renal cortex of control rats and from diabetic rats 14 weeks after induction of diabetes mellitus by streptozotocin (STZ).

- 5 In keeping with the *in vitro* experiments reported above, gremlin mRNA levels were increased in kidneys from diabetic rats, coincident with proteinuria and histologic evidence of diabetic nephropathy (data not shown).
- 10 Nine Male Munich-Wistar uninephrectomized rats were rendered diabetic with streptozotocin, and the RNA extracted as described in Example 3.

- 15 The results are shown in Figs. 20 and 21, which show gremlin mRNA levels in renal cortex of STZ-diabetic rats.

- 20 Fig. 20 is an autoradiograph of gremlin mRNA levels in the kidney cortex of a STZ-diabetic rat (lane 2) and an age matched control (lane 1) analysed by Northern Blot. A band of approximately 4.4kb was detected following hybridisation to the gremlin probe.

- Fig. 21 depicts relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 8

Regulation of mesangial cell gremlin expression by high glucose:
evidence for involvement of TG-β1

5

As indicated above, both high ambient glucose concentrations and cyclic mechanical strain provoke TGF-β1 production by mesangial cells *in vitro* and TGF-β1 appears to be a major stimulus for mesangial matrix accumulation in diabetic glomeruli *in vivo*. To probe the mechanism by which high glucose triggers gremlin expression, primary human mesangial cells were propagated in 5 mM or 30 mM glucose in the presence and absence of anti-TGF-β1 neutralising antibody

10 (1 µg/ml). Treatment of cultures with glucose and anti-TGF-β1 were as described in Example 1 and Example 4, respectively. To assess the role of TGF-β1 as a stimulus for gremlin expression, cells were serum restricted for 24 h in MCDB131 and 0.5% FBS and subsequently treated with 10ng/ml TGF-β1. MCDB131 is a specialised medium for the growth of mesangial cells and is obtained from Clonetics.

20 Initial studies had indicated that TGF-β1 neutralizing antibody (data not shown) blunted glucose-triggered gremlin expression and therefore the ability of TGF-β1 to alter gremlin expression was investigated. The results are shown in Figs. 22 and 23.

25 The addition of exogenous human recombinant TGF-β1 (10 ng/ml, 24 h) to serum restricted (24 h) mesangial cells also augmented

gremlin mRNA levels, suggesting that high glucose enhances gremlin mRNA expression, at least in part, through its ability to stimulate TGF- β 1 expression. In aggregate, these observations suggest the presence of a novel autocrine loop through which TGF- β 1 induces gremlin gene expression and may thereby regulate the activity of mesangial-derived BMPs as hereinafter described.

It was found that gremlin expression in response to high glucose (30 mM, 7 days) was reduced in the presence of anti-TBF- β 1 antibody (data not shown). To further probe the role of TGB- β 1 as a modulator of gremlin expression, mesangial cells were exposed to TGF- β 1 (10 ng/ml) for 24 h (lane 2). Cells cultured in MCDB131 and 0.5% FBS for 24 h served as a control (lane 1).

Fig. 22 is an autoradiograph of gremlin (1), fibronectin (2) and GAPDH (3) mRNA levels analysed by Northern Blot.

Fig. 23 shows relative mRNA levels as estimated by Phosphor Imager quantification. Values were normalised to GAPDH levels.

Example 9

5 High glucose stress induces BMP-2, but not BMP-4 expression in mesangial cells.

As indicated above gremlin is a putative antagonist of BMP-2 and BMP-4. Specifically, gremlin has been recently reported to form heterodimers with BMPs and thereby antagonise BMP signalling (Hsu, 10 D.R., et al. (1998) *supra*). In the present study, RT-PCR was employed as an initial assessment of mesangial cell BMP expression.

15 As an initial assessment of the relationship between gremlin expression and BMP expression, RNA was isolated from mesangial cells grown for 7 days in either 5mM or 30mM glucose. Following reverse transcription with random primers, a primary PCR of the ORF of BMP-2 was performed. This product, which was undetectable on an ethidium stained agarose gel after 30 cycles, was nested to give a predicted product of 446 bp. PCR analysis with BMP-4 and GAPDH specific primers gave predicted products of 378 bp and 452 bp respectively.

20 Fig. 24 depicts representative reactions of 4 independent experiments. 10uL of each PCR reaction was run on 1 % ethidium bromide stained agarose gels.

Whereas little or no BMP-2 mRNA was detected in mesangial cells propagated in 5 mM glucose, a marked induction of BMP-2 expression was observed in cells cultured in 30 mM glucose as shown in Fig. 24.

5

In contrast, BMP-4 expression levels were relatively unchanged. Interestingly, whereas BMP-2 does not stimulate fibronectin expression in mesangial cells *in vitro*, BMP-2 has been recently shown to block mesangial cell proliferation triggered by epidermal growth factor and platelet-derived growth factor (Ghosh Choudhury, G., *et al.*, (1999) *J. Biol. Chem.* 274, 10897-902; Ghosh Choudhury, G., *et al.*, (1999) *Biochem. Biophys. Res. Commun.* 258, 490-6). Our results raise the possibility that TGF- β 1 stimulated expression of gremlin may contribute to mesangial cell proliferative responses in this setting. The influence of gremlin on cell proliferation appears complex, however, and may vary markedly depending on the cell-type and proliferative stimulus. In contrast to the aforementioned potentially pro-proliferative actions, over-expression of the gremlin homologue, drm, causes apoptosis in fibroblasts by an ERK mediated pathway, while cells transformed with oncogenes such as v-mos show suppressed drm expression (Topol, L.Z., *et al.*, (1997) *Mol. Cell. Biol.* 17, 4801-10). Similarly, over-expression of DAN, another cysteine knot super-family member with homology to drm/gremlin, retards fibroblast entry into S phase (Ozaki, T., *et al.*, (1995) *Cancer Res.* 55, 895-900).

25

In summary, our results demonstrate that the DAN family member gremlin is induced in diabetic nephropathy *in vivo* and implicate both metabolic and hemodynamic stress as stimuli for gremlin expression.

5 The findings that high glucose-triggered gremlin expression is mimicked by addition of exogenous TGF- β 1, blunted by anti-TGF- β 1 neutralising antibody, and occurs in association with induction of mesangial cell BMP-2 suggests the presence of a novel autocrine loop which may limit the bioactivity of TGF- β 1 superfamily members and
10 modulate mesangial cell proliferation within the diabetic mesangium.
The further elucidation of the functional interactions of the DAN family of secreted proteins, such as gremlin, with TGF- β 1 superfamily members may shed light on the complex multi-pronged molecular events that perturb cell proliferation and matrix production in diabetic
15 glomerulosclerosis.

Claims: -

1. A method for identifying a gene having a role in the presentation of diabetic nephropathy, which method comprises culturing mesangial cells in a medium in the presence of a concentration of glucose sufficient to induce differential expression of a gene susceptible to such differential expression and identifying the gene so induced.
- 10 2. A method according to Claim 1, wherein the mesangial cells are cultured in the presence of a concentration of glucose sufficient to induce up-regulation of a gene susceptible to such up-regulation.
- 15 3. A method according to Claim 1 or 2, wherein the concentration of glucose is greater than 5 mM.
4. A method according to any preceding claim, wherein the mesangial cells are subjected to mechanical strain.
- 20 5. A method according to any preceding claim, wherein transforming growth factor $\beta 1$ (TGF- $\beta 1$) is added to the culture medium.
- 25 6. A method according to any preceding claim, wherein the differentially expressed gene is identified by suppression subtractive hybridisation.

7. A method according to any one of Claims 1-6, wherein the possibility of differential expression due to hyperosmolarity is excluded.

8. A method according to any one of Claims 1-7, wherein the gene
5 so differentially expressed is a gene which includes a sequence selected from:

1) SEQ ID NOS: 1-3;

10 2) SEQ ID NO: 4;

3) SEQ ID NO: 5; and

4) SEQ ID NO: 6.

15

9. Use of a gene identified by a method according to any one of Claims 1-8, as a diagnostic marker for the progression and presentation of diabetic nephropathy.

20 10. Use of a gene identified by a method according to any of Claims 1-8, as an index of disease activity and the rate of progression of diabetic nephropathy.

25 11. Use of a gene identified by a method according to any of Claims 1-8, as a basis for identifying drugs for use in the prevention and/or therapy of diabetic nephropathy.

12. A gene containing a sequence selected from any one of sequences 1-3, 5 and 6 according to Claim 8.

1/24




Fig. 1

2/24




Fig. 2

3/24




Fig. 3

4/24

```

rat: 1      atctccacccGgttaccaatgacaatacTttctgcagGctggagaagcagagTcgTctc 60
||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 783   atctccacccgagttaccaatgacaataccttctgcagactggagaagcagagccgcctc 842

rat: 61     tgcatggtcaggccctgTgaagctgacctAgaggaaaaacattaagaagggaaaaagtgc 120
||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 843   tgcatggtcaggccctgcgaagctgacctggaggaaaacattaagaagggaaaaagtgc 902

rat: 121    atccggacGcctaaaatTgccaagcctgtcaagttgagcttctggctgcaccagtgt 180
||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 903   atccggacacctaaaatcgccaagcctgtcaagttgagcttctggctgcaccagtgt 962

rat: 181    aagacCtacCgggctaagttctgTggggtgtgcacGgacggccgctgctgcacacccgac 240
||||||| ||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 963   aagacatacagggctaagttctgcgggtgtgcacagacggccgctgctgcacacccgac 1022

rat: 241    agaaccaccacActgccggtgagttcaaGtgccccCatggcgaAatcatgaaaaagaac 300
||||||||||| ||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 1023  agaaccaccactctgccagtggagttcaaattgccccatggcgagatcatgaaaaagaat 1082

rat: 301    atgatgttcatcaagacacctgtgcctgccattacaactgtcc 341      (SEQ ID NO: 29)
||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||||||||| ||||| |
mouse: 1083  atgatgttcatcaagacacctgtgcctgccattacaactgtcc 112      (SEQ ID NO: 30)

```

Fig. 4

5/24

rat: 1 ISTRVTNDNTFCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKIAKPVKFELSGCTSV 180
mouse: 216 ISTRVTNDNTFCRLEKQSRLCMVRPCEADLEENIKKGKKCIRTPKIAKPVKFELSGCTSV 275

rat: 181 KTYRAKFCGVCTDGRCCTPHRTTLPVEFKCPHGEIMKKNMMFIKTCACHYNC 339 (SEQ ID NO: 31)
mouse: 276 KTYRAKFCGVCTDGRCCTPHRTTLPVEFKCPDGEIMKKNMMFIKTCACHYNC 328 (SEQ ID NO: 32)

Fig. 5

6/24

bp




Fig. 6

7/24




Fig. 7

8/24




Fig. 8

9/24




Fig. 9

10/24




Fig. 10


11/24

Fig. 11

12/24




Fig. 12

13/24




Fig. 13

14/24




Fig. 14

15/24

1 GCGGCCGCACCTAGCGCCACCGCTGCAAAGCGCAGGGCCCGAGGACCCGCCACTGACAGTATGAGCCGCACAG
M S R T A
76 CCTACACGGTGGGAGCCCTGCTTCCTCTGGGACCCCTGCTGCCGGCTGCTGAAGGAAAAGAAAGGGTCCC
Y T V G A L L L L G T L L P A E G K K G S Q
151 AAGGTGCATCCCCCGCAGACAAGGGCCAGCACAACTGACTCAGAGCAGACTCAGTGCAGGCCAGCAGCTGCTGCT
G A I P P P D K A Q H N D S E Q T Q S P Q Q P G S
226 CCAGGAACGGGGGGGGCAAGGGGGGGCACTGCCATGCCGGGGAGGGAGGTGCTGGAGTCAGGCCAGAAGAGG
R N R G R G Q R G T A M P G E E V L E S S Q E A
301 CCCTGATGAGCGGCCAAATACCTGAAAGCGAGACTGGTGCAGAACCCAGCCGCTTAAGCAGACCATCCAG
L H V T E R K Y L K R D W C K T O P L K Q T I H
376 AGGAAGGCTGCAACAGTCGCCACCATCATCAACCCTCTGTTACGCCAGTGCACACTTCTACATCCCCAGGC
E G C N S R T I I N R F R C Y G Q C N S F Y I P R H
451 ACATCGGAAGGAGGAAGGTTCTTCAGTCTGCTCTCTGCAAGGCCAAGAAATTCACTACCATGATGGTCA
I R K E E G S F Q S C S C F C K P K K F T T M M V T
526 CACTCAACTGCCCTGAACTACAGGCCACCTACCAAGAAGAAGAGAGTCACACGTGTAAGCAGCTGTTGCATAT
L N C P E L Q P P T K K K R V T R V K Q C R C I S
601 CCATCGATTGGATAAGCCAATCCAGGTGACCCAGCATGTCCTAGGAATGCAAGCCCCAGGAAGTCCCAGACC
I D L D
676 TAAAAACACAGATTCTTACTGGCTAAACCTAGAGGCCAGAAGAACCCCCAGCTGCCCTCTGGCAGGAGCTG
751 CTTGTCGTAAGTCGTGTCATGAGTGGATGGTGCCTGTTAGACACCAAGAGAAAACAGCTCT
826 CTGCTAGAGGACATCCCTAATTTGTAACATCTGCTTAAATGGGATGTAACAGAACCCACTCACCCCG
901 CTACATCTAAAGGGGGGGGGCCGGTCTGGTCTGGTCTGAGTCTGTTAGTGTGCTCCCTGGGAGCAATCT
976 CTTCGGAATGAATGTTCTGAAAGGGCTCTCTGAGGCCAAGAGACCTGTTAGTGTGCTTCAGACATGGA
1051 AAAGTCTTTAACCTGCTGCTGCATCTCTCTCTCTCTCACAATCCATCTCTTAAAGTGTAGT
1126 GACTATGTCAGTCAATCTCTGTTGCAAGGTTCTAAATTAACTTAACCATGATGCAATGTTTTCA
1201 TTTGTAAGACCTCCAGACTCTGGAGAGGCTGGTGGCAAGGCAAGGACAGAAGCAGATGTTAGGAGAAAGG
1276 AGGTGGAGGGTGGAGGCCAATCAGGTCGCAAGGAAAGTCACTGTTCTAGTATTAAACAGAACCCAACTGAAAC
1351 AGAACACAGGCTGATGCTCTGAGAAAGTCTTCTAGTATTAAACAGAACCCAACTGAAACAGAGGAGAAATG
1426 GATTGGCCAGAAAGTGTAACTTTGGCCGTTGCAATCTGCTCAACCTAACACCAAACTGAAACATAAAACTG
1501 ACCACTCTATGTCGGGACCAAGCAAGTAGCTAAACCAACACTCTGCTTGTCCCTCAGGTGAAAG
1576 GAGAGGTAGTTAGAAGACTCTCTGCTAGGGGAAATTAACTAACAAACCKCAGGGCTGAAATTCTAAACT
1651 TTCCCTTATGTTAGTCAGTCATTCCATTCTCATTCTGAGGCTACTTCCATTCTGAGGCCACTAACTTG
1726 ATTGATAAAAGATCCTGCTCTGCTGAGTGTACCTGACAGTAAGTCTAAAGATGARAGAGTTAGGGACTACTCTG
1801 TTTAGCACAGARATATTGGGGGCTTTTTCTTAAACTTGTCAAGGAGATTGGCTARAGAGAAGACGCCA
1876 GACTAAGGAAATAAGGGRATTGCTCTGGCTAGAGAGTAAGTTAGGTGTTAACCTGTTAGGAGAAATGTAAGGG
1951 TATGACCTCCCTTCTTATGTCCTACTGGAGGCTACTGGAGGATCTGAGGCTAGCATGATGTA
2026 TTAGCTGTTCATCTGCTACTGGTGGATGGACATAACTATTGTAACTATTCACTGTTACTGGTAGGCACTGCTC
2101 TCTGATTAACCTGGCTACTGGCAATGGCTACTTAGGATTGATCTAAGGGCAAAGTCAGGGTGGTGAACCT
2176 TATTGACTTGGATTGGTTAACCTGTTCTTCAAGCTGGAGGTTTATATACAAACCTCTGAAATCTT
2251 TTGCTCTGTATCTCTCAGGCCCTGAGCCAAGTCTCTGAGTCTATGAAATGGGAAACAAACACTGCA
2326 GTGCCGATCAAGGCTCTGGCATTAGAGAACCCCTGCAACTCGAGAACGCTGTTTCTGTTTGG
2401 TCCAGTGTCTCCCTAACAACCTAAACAGGAGCCATTCAAGGCCAGATTTAAACACCCAAATGTTG
2476 GGTCTGATTCTCAAACCTTAAACTCACTACTGATGATCTCAGCTAGGCAATTTGCTAAAC
2551 TGTTGGTTGATACGTGACCCACCCAAATCTGTTATGTCCTGAGGCTACATTCTCCTGAAAG
2626 TGGATTTAACTAACAGCACAAATGCTAACGGCAGAATTGGAGGGAGAGAAGAAAAGGGAAAGAACAGAG
2701 ATGTAACACACACCAGGGAGGAAATGACATTCAAGAACAGCAACACTGAAATTCTCTGTTGTTAACTC
2776 TGCCACAAGATGCAATTCTGTTAAATGGAGATGACTTAAGTGTGAGCTGAGTCTGGCAGCAGTAATCT
2851 ACAGTCTGACATAAGTGCAGATTGGCTCAAGTAAGAGAAATTCTCCTAACACTAACTACTGGATAATCA
2926 GCAGCGTAACCTCTAAACCATACTAACAGGCCAAAGGGAAATATCTGTTCTCTACTGCTCTATATAA
3001 GACTAGTACAAATGTTGTTGCTTCAACCTTCATTGAAATGCCATATCTATACCAATTATTTATCGAGTC
3076 TGATGATGTAATGATATATTCTTATTATGAGGATATTGGCAAGATATTGTGTTGCTTGTGATCAT
3151 ACCTTAAATAATACTGCAACACAAATGAAATTGATGACTACATTGCTCTGGCATTAAGGAAA
3226 ACACACATCTGGAGACTGTCAGTGGTCTTATTGTTACTGTGAGGTTAAGGAGTGAAGTGA
3301 TGGAGGGAGGGATAATTCTCACTGTGAGGTTAAGGAGAAATCTAAAGGAAAGTGTGTTATTAA
3376 TACTTCAAACTCTTGGTCACTGTGATTCAAGCATGTTCTTCTCTTATGACTTTCTGAGTGG
3451 GCAAGAAGAAGCTGACACACGGTAGTGTGTTAGACTCTTATCTGTCAGGGAAACAAATCTGACCCAGC
3526 TGAACATGTCCTCTGACTGTCAGGCCGTAACCTTATTGTTAAGGAGACTTACAGTGC
3601 AGGCAATTAAAGAAGACTTAAATGTTATTGTTAAGGAGAAATCTAAAGGAAAGTGGATAACAGAAC
3676 TGATGACTAGTTACACATAAGTCCTTTAAGGAGAAATCTAAAGGAAAGTGGATAACAGAACATTATA
3751 AGTGTCAAGTAAATGCTAAAGTGTGAAAGTGTGTTCTGAGTCTATTGACATTCTCAAG
3826 GATTTATGTCGTTAAATCTTAAACAGGCCAAAGAATTATGACTGAGTGTGAGTGG
3901 ATGAAAGGGGGAGTTGATGTCATGTCATAAAACTAATTGGCTCAAGTTGATGTCAGT
3976 TCACCCCAATAATGTTCTATAGCCTTGGCTAAAGGCAACTAATAAATTAAACCTTATTCTC
AAAAAAAAAA

(SEQ ID NO: 33)

Fig. 15

16/24




FIG. 16

17/24




FIG. 17

18/24




FIG. 18

19/24




FIG. 19

20/24




FIG. 20

21/24




FIG. 21

22/24




Fig. 22

23/24





Fig. 23

24/24**Fig. 24**

SEQUENCE LISTING

<110> HiberGen Limited
University College Dublin, Nat Uni of Ire, Dublin
Brady, Hugh Redmond
Godson, Catherine Mary
Martin, Finian Martin

<120> Identification of genes having a role in the presentation of diabetic nephropathy

<130> P00-18-PCT

<140>

<141>

<150> 990157

<151> 1999-02-26

<160> 33

<170> PatentIn Ver. 2.1

<210> 1
<211> 598
<212> DNA
<213> Homo sapiens

<400> 1
ttgaaatagt tcttgcttta taaaaatagt actgcgatta aaaaaaaagc acttctgcc 60
aaggaaccat gttccaacac cgcaacaacag gtgttctgtct taaaacagagt aagatacaccc 120
accccccattcc atcccttcct tccctgttcc cctcccaact tgtagttgtgt cattcgacc 180
agtgtctgg gtggtaggga tgctacagcc acctaaggca aggagccctg ggaggtggga 240
gggcttgcatt ggttaagcac accagaactg aagcgaaaaa gggtcagctg tcttcatcta 300
gaatctctgg atgttccttc cagaaagcat ccccgatgat atcgcagtgc aagggactg 360
gctttgtcct ggtccgggtc actgccatct tttttccctc catttctgtt ggcagcttaa 420
tttctttgt catcaattca tccacattct gccatatcaa cacagtccct ttcctataaca 480
tcggcagctc attattatag ttgtatgtga attcagaaaa caaaaatctca ttcttgcgtc 540
ctgnaagagt tccctgtaat ctcccttggg cttgtactgg tgttagtcca gattgttgc 598

<210> 2
<211> 761
<212> DNA
<213> Homo sapiens

<400> 2
ggtcctttaa agtctggtttg ctgggataca ccacgactct tccggtaaaa gcctggggga 60

tacagaaggg gctrgtcctc aaagtaatcc cgccaataaaa acayatagct ggaggcaaac 120
 tgggaggyca cgtgagtcat gaacttact ggctttctt ttaaaccatat tggtttccg 180
 cttgwacaca aagctgtact catcaactcg tccataacgc gatcacaata tcctctagtt 240
 ctccatcac agtctgcgca cattggtca tcagctggag agcacggctg tcattgggtt 300
 ttgcaaagtt gtgcttctca gcaaaccat ggaaattccg gccgtccagc cgnactacca 360
 cccagcagtg tgccaggcag gtgtcgtcag cctcgaagtc cctcacgtac tcgaacttgc 420
 ttttgccat ggtcgcccc aatctcaggt accgtctcag agtgatggaa atggtggcca 480
 aggaatcgtg aacctaact ttacaggcgc cccacatct acacgcggaa aggaaaggc 540
 cagatagccc cgccccggaa gtgttctt cgtggctact cttagccgtag ggcggtcata 600
 gtctctctcg sctccctcg kagttctaa mcyyccaggg aaaraggatg gaggtttagg 660
 ttccctccgtt agcaccttcc acgcttgctt cttccctcctc ccggtctgctgcaatcagt 720
 ctcacgaggt tttaaaaat tatttttat ctgctggcct t 761

<210> 3
<211> 393
<212> DNA
<213> Homo sapiens

<400> 3
atgacacaaa tattaggatt ttattttac tattatccac cagcaacaag atatcaaaca 60
ctggttctgt gattatcaa tggtaaaaaa gttgaataaa tcaatttagt atacccatat 120
gttggaatat tgagtccatt tttctttaa aaatcacact ttggaataat ttagtatact 180
ggcaatgct caagctgagt ggaaaaatataaaacattg tataggcgaa taattccat 240
cttgtgcatt ccctgtgtaa acctacatac aaaaaagaa aaaagactga aaggaaccat 300
ccacaatgct ttgatcgaaa aagacggaga aacaaagtgt taattttctt aactatagtt 360
ttnggtgtat tccagattt ctacaagttt ata 393

<210> 4
<211> 435
<212> DNA
<213> Homo sapiens

<400> 4
gtactttgga ttggtaac ctgtttctt caagcctgag gttttatata caaactccct 60
gaataactctt ttgccttgt atcttctcag cctcctagcc aagtccatg taatatggaa 120
aacaaacact gcagacttga gattcagttt ccgatcaagg ctctggcatt cagagaaccc 180
ttgcaactcg agaagctgtt tttatccgt tttgtttt atccagtgtt ctcccatcta 240
acaactaaac aggagccatt tcaaggcgaa agatattta aacacccaaa atgggtgggt 300
ctgattttca aactttaaa attcactact gatgattctg cactgtaagg cgaatttgg 360
ccaaacacat aagtgtgtt gttttgtata cactgtatga cccacccca aatcttgc 420
ttgtccacat tctcc 435

<210> 5
<211> 273
<212> DNA

<213> Homo sapiens

<400> 5
agaagcaatt taggaancn acagnaaana aatgctgttt tataggagag aaaacacggc 60
acaccaaggt taagtagttt gtagacgatg ttgaataggt tcaggtacag gtcaatgcag 120
tgatgaggaa agcacctang tataacttgac agatagtccc ctttgcttaa cacccaaactc 180
ctccaccctg tgcagttnn cttgtgccag tgatcacagg attcgctgag tgaattacca 240
taattggatt taattcacga agggatgtt ttc 273

<210> 6

<211> 309

<212> DNA

<213> Homo sapiens

<400> 6
attgatagag gccctgttc atgacatttc atgagttca atatgttgtt cagcatgttg 60
tgaggtgact ctcagccct ttcccactga gatggactgt ggtgatgctg tgagggtgtg 120
actgacacac cttcatgtgc ccaagcatgg gtttgatcac aggtcacatg cagttttgg 180
catagtaaat gtatcattgt tctttcctc cctcctaaag gaaacagagg aatccacctg 240
tatgagagtg ccatgttaggg ataaaacttaa aggacagatg acacattggt catgttcgtg 300
ataaggaaa 309

<210> 7

<211> 20

<212> DNA

<213> Homo sapiens

<400> 7
accacagtc accatcac 20

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

<400> 8
tccaccaccc tggctgtta 20

<210> 9

<211> 20

<212> DNA

<213> Homo sapiens

<400> 9

ggtcttcctg gcttaaaggg 20

<210> 10
<211> 20
<212> DNA
<213> Homo sapiens

<400> 10
gctggtcagc cctgtagaag 20

<210> 11
<211> 20
<212> DNA
<213> Homo sapiens

<400> 11
ccaggagttc caggattca 20

<210> 12
<211> 20
<212> DNA
<213> Homo sapiens

<400> 12
ttttggtccc agaaggacac 20

<210> 13
<211> 18
<212> DNA
<213> Homo sapiens

<400> 13
cgaaatcaca gccagtag 18

<210> 14
<211> 18
<212> DNA
<213> Homo sapiens

<400> 14
atcacatcca cacggtag 18

<210> 15
<211> 20
<212> DNA
<213> Homo sapiens

<400> 15
ctaagacctg tggaatggc

20

<210> 16
<211> 21
<212> DNA
<213> Homo sapiens

<400> 16
ctcaaagatg tcattgtccc c

21

<210> 17
<211> 20
<212> DNA
<213> Homo sapiens

<400> 17
atgagccgca cagcctacac

20

<210> 18
<211> 23
<212> DNA
<213> Homo sapiens

<400> 18
ttaatccaaa tcgatggata tgc

23

<210> 19
<211> 21
<212> DNA
<213> Homo sapiens

<400> 19
ctcagcctcc tagccaagtc c

21

<210> 20
<211> 21
<212> DNA

<213> Homo sapiens

<400> 20

gtattgtcca cattctccaa c

21

<210> 21

<211> 20

<212> DNA

<213> Homo sapiens

<400> 21

atgagccgca cagcctacac

20

<210> 22

<211> 21

<212> DNA

<213> Homo sapiens

<400> 22

gtattgtcca cattctccaa c

21

<210> 23

<211> 20

<212> DNA

<213> Homo sapiens

<400> 23

gagagtacaca cgtgtgaagc

20

<210> 24

<211> 19

<212> DNA

<213> Homo sapiens

<400> 24

aggaggatgc aagcacagg

19

<210> 25

<211> 29

<212> DNA

<213> Homo sapiens

<400> 25

cgccggatcct gcttcttaga cggaactgcg

29

<210> 26

<211> 20

<212> DNA

<213> Homo sapiens

<400> 26

tttgctgtac tagcgacacc

20

<210> 27

<211> 18

<212> DNA

<213> Homo sapiens

<400> 27

caagatgaac acagctgg

18

<210> 28

<211> 18

<212> DNA

<213> Homo sapiens

<400> 28

gctcaggata ctcaagac

18

<210> 29

<211> 341

<212> DNA

<213> Rattus sp.

<400> 29

atctccaccc gggttaccaa tgacaatact ttctgcaggg tggagaagca gagtcgtctc 60
tgcatggta gcccctgtga agctgaccta gaggaaaaca ttaagaaggg caaaaagtgc 120
atccggacgc ctaaaattgc caagcctgtc aagtttgagc tttctggctg caccagtgt 180
aagaccttacc gggctaagtt ctgtgggtg tgcacggacg gccgctgctg cacaccgcac 240
agaaccacca cactgccgt ggagttcaag tgcccccatg gcgaaatcat gaaaaagaac 300
atgatgttca tcaagacctg tgcctgccat tacaactgtc c 341

<210> 30

<211> 341

<212> DNA

<213> Mus sp.

<400> 30
atctccaccc gagttaccaa tgacaatacc ttctgcagac tggagaagca gagccgcctc 60
tgcgttca ggcctgcga agctgacctg gaggaaaaca ttaagaaggg caaaaagtgc 120
atccggacac ctaaaatcgca agcctgtc aagtttgagc tttctggctg caccagtgtg 180
aagacataca gggctaagtt ctgcgggtg tgcacagacg gccgctgctg cacaccgcac 240
agaaccacca ctctgccagt ggagttcaaa tgccccatg gcgagatcat gaaaaagaat 300
atgtatgttca tcaagacctg tgcctgccat tacaactgtc c 341

<210> 31
<211> 113
<212> PRT
<213> Rattus sp.

<400> 31
Ile Ser Thr Arg Val Thr Asn Asp Asn Thr Phe Cys Arg Leu Glu Lys
1 5 10 15
Gln Ser Arg Leu Cys Met Val Arg Pro Cys Glu Ala Asp Leu Glu Glu
20 25 30
Asn Ile Lys Lys Gly Lys Cys Ile Arg Thr Pro Lys Ile Ala Lys
35 40 45
Pro Val Lys Phe Glu Leu Ser Gly Cys Thr Ser Val Lys Thr Tyr Arg
50 55 60
Ala Lys Phe Cys Gly Val Cys Thr Asp Gly Arg Cys Cys Thr Pro His
65 70 75 80
Arg Thr Thr Thr Leu Pro Val Glu Phe Lys Cys Pro His Gly Glu Ile
85 90 95
Met Lys Lys Asn Met Met Phe Ile Lys Thr Cys Ala Cys His Tyr Asn
100 105 110
Cys

<210> 32
<211> 113
<212> PRT
<213> Mus sp.

<400> 32
Ile Ser Thr Arg Val Thr Asn Asp Asn Thr Phe Cys Arg Leu Glu Lys

1

5

10

15

Gln Ser Arg Leu Cys Met Val Arg Pro Cys Glu Ala Asp Leu Glu Glu
 20 25 30

Asn Ile Lys Lys Gly Lys Lys Cys Ile Arg Thr Pro Lys Ile Ala Lys
 35 40 45

Pro Val Lys Phe Glu Leu Ser Gly Cys Thr Ser Val Lys Thr Tyr Arg
 50 55 60

Ala Lys Phe Cys Gly Val Cys Thr Asp Gly Arg Cys Cys Thr Pro His
 65 70 75 80

Arg Thr Thr Thr Leu Pro Val Glu Phe Lys Cys Pro Asp Gly Glu Ile
 85 90 95

Met Lys Lys Asn Met Met Phe Ile Lys Thr Cys Ala Cys His Tyr Asn
 100 105 110

Cys

<210> 33

<211> 4049

<212> DNA

<213> Homo sapiens

<400> 33

gcggccgac tcagcgccac gcgtcgaag cgcaaggcccc gaggaccgc cgcaactgaca 60
 gtatgagccg cacagctac acgggtggag ccctgcttct cctcttgggg accctgctgc 120
 cggctgctga agggaaaaag aaagggtccc aaggtgccat ccccccggca gacaaggccc 180
 agcacaatga ctcagagcag actcagtcgc cccagcagcc tggctccagg aaccgggggc 240
 ggggccaagg gcggggcact gccatggccg gggaggaggt gctggagtcc agccaagagg 300
 ccctgcattgt gacggagcgc aaataacctga a诶cgagactg gtgaaaacc cagccgctta 360
 agcagaccat ccacgaggaa ggctgcaaca gtcgcaccat catcaaccgc ttctgttacg 420
 gccagtgcaa ctctttctac atccccaggc acatccggaa ggagaaggt tcctttcaagt 480
 cctgctcctt ctgcaagccc aagaaattca ctaccatgt ggtcacactc aactgccctg 540
 aactacagcc acctaccaag aagaagagag tcacacgtgt gaagcagtgt cgttgcata 600
 ccatcgattt ggattaagcc aaatccaggt gcacccagca tgtccttagga atgcagcccc 660
 aggaagtccc agacctaaggaa caaccagatt cttaacttggc tttaaacctag aggccagaag 720
 aaccccccacg tgcctcctgg caggaggctg cttgtcgta gttcgtgtgc atgagtgtgg 780
 atgggtgcct gtgggtgttt ttagacacca gagaaaaacac agtctctgct agagagcact 840
 ccctattttg taaacatatc tgcttaatg gggatgtacc agaaacccac ctcaccccg 900
 ctcacatcta aaggggcgagg gccgtggct gttctgact ttgtgtttt gtgcctcct 960
 ggggaccaga atctccttgc ggaatgaatg ttcatggaag aggctcctct gagggcaaga 1020
 gacctgtttt agtgctgcat tcgacatgga aaagtccctt taacctgtgc ttgcacatcctc 1080

ctttcctcct ctcctcaca atccatctct tcttaagttt atagtacta tgtcagtcta 1140
 atctctgtt tgccaagggtt cctaaattaa ttcaactaac catgatgcaa atgttttca 1200
 ttttgtgaag accctccaga ctctggaga ggctgggtg ggcaaggaca agcaggatag 1260
 tggagtgaga aaggggaggt ggagggtgag gccaaatcag gtccagcaaa agtcagtagg 1320
 gacattgcag aagcttggaaa ggccaataacc agaacacagg ctgatgcttc tgagaaagtc 1380
 ttttcctagt atttaacaga acccaagtga acagaggaga aatgagattt ccagaaagtg 1440
 attaactttg gccgttgcaa tctgctcaaa cctaacacca aactgaaaac ataaatactg 1500
 accactccta tgttcgacc caagcaagtt agctaaacca aaccaactcc tctgcttgc 1560
 ccctcagggtg gaaaagagag gtagttttaga actctctgca taggggtggg aattaatcaa 1620
 aaacckcaga ggctgaaatt cctaataacct ttccctttagt gttttatag tcagctcatt 1680
 tccattccac tatttcccat aatgctctg agagccacta acttgattga taaagatcct 1740
 gcctctgctg agtgtacctg acagtaagtc taaagatgar agattttagg gactactctg 1800
 ttttagcaag aratattktg ggggtcttt tgttttact attgtcagga gattggctt 1860
 ragagaagac gacgagagta aggaaataaa gggrattgcc tctggctaga gagtaagtt 1920
 ggtgttaata cctggtagaa atgttaaggga tatgacctcc ctttctttat gtgctactg 1980
 aggatctgag gggaccctgt taggagagca tagcatcatg atgtatttagc ttttcatctg 2040
 ctactggttg gatggacata actattgtaa ctattcagta tttactggta ggcactgtcc 2100
 tctgattaaa cttggcctac tggcaatggc tacttaggat tgatctaagg gccaaagtgc 2160
 agggtgggtg aactttattt tactttggat ttggtttacc tgttttcttc aagcctgagg 2220
 ttttatatac aaactccctg aatactctt ttgccttgc tcttctcagc ctccctagcca 2280
 agtcctatgt aatatggaaa acaaacactg cagacttgag attcagttgc cgatcaaggc 2340
 tctggcattc agagaaccct tgcaactcga gaagctgttt ttatTCGTT tttgtttga 2400
 tccagtgctc tcccatactaa caactaaaca ggagccattt caaggcggga gatattttaa 2460
 acacccaaaa tgggggtct gattttcaaa cttttaaact cactactgat gatttcacg 2520
 cttaggcgaat ttgtccaaac acatagtgtg tgggtttgtt atacactgtt tgaccccacc 2580
 ccaaactttt gtattgtcca catttccaa caataaagca cagagtggat ttaattaagc 2640
 acacaaatgc taaggcagaa ttttgggggtt gggagagaag aaaagggaaa gaagctgaaa 2700
 atgtaaaacc acaccaggaa ggaaaaatga cattcagaac cagcaaacac tgaatttctc 2760
 ttgttggttt aactctgcca caagaatgca atttcgtttaa tggagatgac ttaaggttgc 2820
 agcagtaatc ttcttttagg agcttgtacc acagtctgc acataagtgc agattggct 2880
 caagtaaaga gaatttcctc aacactaact tcactggat aatcagcagc gtaactaccc 2940
 taaaagcata tcacttagcca aagagggaaa tatctgttct tcttactgtg cctatattaa 3000
 gactagtaca aatgtgggtt gtcttccaac tttcattgaa aatgccatat ctataccata 3060
 ttttattcga gtcactgtatg atgtaatgtt atatTTTTC attattatag tagaatattt 3120
 ttatggcaag atatttggg tcttgatcat acctattaaa ataatgccaac acaccaaata 3180
 tgaattttat gatgtacact ttgtgttgg cattaaaaaga aaaaaacaca catcctggaa 3240
 gtctgttaagt tggttttgt tactgttagt cttcaagtt aagagtgtaa gtggaaaatc 3300
 tggaggagag gataatttcc actgtgtgaa atgtaaatgaa taaaatgaaa agttatggtt 3360
 atttaatgtt attattactt caaatccctt ggtcaactgtg atttcaagca tgttttctt 3420
 ttctccctta tatgacttcc tctgagttgg gcaaaagaaga agctgacaca ccgtatgtt 3480
 tttaggtctt ttatctggtc agggaaaaca aaatcttgc acagctgaac atgtcttcc 3540
 gagtcagtgc ctgaatctt attttttaaa ttgaatgttc cttaaagggtt aacattctt 3600
 aagcaatatt aagaaagact taaaatgtt ttttggaaaga ctacgatgc atgtatacaa 3660
 acgaatagca gataatgtatg actagttcac acataaagtc cttttaagga gaaaatctaa 3720
 aatgaaaagt ggataaacag aacattata agtgatcagt taatgcctaa gagtggaaagt 3780
 agttctatttgc acattcctca agatattttaa tatcaactgc attatgtattt atgtctgctt 3840
 aaatcatttta aaaacggcaa agaatttat agactatgag gtaccttgct gtgttaggagg 3900
 atgaaagggg agttgatagt ctcataaaac taatttggct tcaagttca tgaatctgtt 3960

actagaat~~t~~ aatttcacc ccaataatgt tctatata~~gc~~ ctttgctaaa gagcaactaa 4020
taaattaaac ctattctt~~c~~ aaaaaaaaaa 4049

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IE 00/00026

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLMES D I ET AL: "Identification of glucose -regulated genes in human mesangial cells by mRNA differential display." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 SEP 8) 238 (1) 179-84. XP000919240 the whole document —	1-7
A	DATABASE EMSTS 'Online! EMBL, Heidelberg; Accession Number G38490, 24 June 1998 (1998-06-24) MYERS R.M.: "Human STSs 1998" XP002143063 abstract — —/—	12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

20 July 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3018

Authorized officer

Luzzatto, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IE 00/00026

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE EMEST 'Online! EMBL, Heidelberg; Accession Number AA071138, 4 October 1996 (1996-10-04) HILLIER L. ET AL.: "Generation and analysis of 280000 human expressed sequence tags" XP002143064 abstract	12
P,X	MURPHY M ET AL: "Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 FEB 26) 274 (9) 5830-4., XP002142860 the whole document	1-7
P,X	DATABASE EMHUM 'Online! EMBL, Heidelberg; Accession Number AK000553, 22 February 2000 (2000-02-22) SUGANO S. ET AL.: "NEDO human cDNA sequencing project" XP002143065 abstract	12
P,X	DATABASE GENESEQ 'Online! Derwent; Accession Number Z52443 (WO-A-9957144), 24 February 2000 (2000-02-24) HILLMAN J.L. ET AL.: "New peptides useful for diagnosis, prevention and treatment of cancer and immune disorders" XP002143066 abstract	12
X	DATABASE EMEST 'Online! EMBL, Heidelberg; Accession Number N52279, 18 February 1996 (1996-02-18) HILLIER L. ET AL.: "The WashU-Merck EST project" XP002143067 abstract	12